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ABSTRACT 
In the 30 years since the Center for Disease Control's Morbidity and Mortality Weekly 
Report published the first mention of what later was determined to be AIDS (Acquired 
immunodeficiency syndrome) and HIV (Human immunodeficiency virus) recognized as 
the causative pathogen, much has been done to understand this disease’s pathogenesis, 
development of drugs and emergence of drug resistance under selective drug therapy. 
Highly Active Antiretroviral Therapy (HAART), a combination of drugs that includes 
HIV-1 reverse transcriptase, protease, and more recently, integrase and entry inhibitors, 
have helped stabilize the HIV prevalence at extraordinarily high levels.  Despite the 
recent stabilization of this global epidemic, its dimensions remain staggering with 
estimated (33-36million) people living with HIV-AIDS in 2007 alone. This is because the 
available drugs against AIDS provide treatment for infected individuals, but HIV evolves 
rapidly under drug pressure and develops resistant strains, rendering the therapy 
ineffective. Therefore, a better understanding underlying the molecular mechanisms of 
viral infection and evolution is required to tackle drug resistance and develop improved 
drugs and treatment regimens. 
HIV-1 protease is an important target for developing anti-HIV drugs. However, resistant 
mutations rapidly emerge within the active site of the protease and greatly reduce its 
affinity for the protease inhibitors. Frequently, these active site drug resistant mutations 
co-occur with secondary/ non-active site/ associated or compensatory mutations distal to 
the active site. The role of these accessory mutations is often suggested to be in 
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maintaining viral fitness and stability of protease. Many of the non-active site drug 
resistant mutations are clustered in the hydrophobic core in each monomer of the 
protease. Molecular dynamic simulation studies suggest that the hydrophobic core 
residues facilitate the conformational changes that occur in protease upon ligand binding. 
There is a complex interdependence and interplay between the inherent adaptability, drug 
resistant mutations and substrate recognition by the protease. Protease is inherently 
dynamic and has wide substrate specificity. The PI (protease inhibitor) resistant 
mutations, perhaps, modulate this dynamics and bring about changes in molecular 
recognition, such that, in resistant proteases, the substrates are recognized specifically 
over the PIs for the same binding site. In this thesis research, I have investigated these 
three complementary phenomena in concert. 
Chapter II examines the importance of hydrophobic core dynamics in modulating 
protease function. The hydrophobic core in the WT protease is intrinsically flexible and 
undergoes conformational changes required for protease to bind its substrates. This study 
investigated if dynamics is important for protease function by engineering restricted vs. 
flexible hydrophobic core region in each monomer of the protease, using disulfide 
chemistry. Under oxidizing conditions, disulfide bond established cross-link at the 
interface of putative moving domains in each monomer, thereby, restricting motion in 
this region. Upon reduction of the disulfide bond, the constraining influence was reversed 
and flexibility returned to near WT. The disulfide cross-linked protease showed 
significant loss of function when tested in functional cleavage assay. Two protease 
variants (G16C/L38C) and (R14C/E65C) were engineered and examined for changes in 
 viii 
structure and enzymatic activity under oxidizing and reducing conditions. (R14C/E65C) 
was engineered as an internal control variant, such that cysteines were engineered 
between putative non-moving domains. Structurally, both the variants were very similar 
with no structural perturbations under oxidizing or reducing conditions. While significant 
loss in function was observed for (G16C/L38C) only under oxidizing conditions, 
(R14C/E65C) did not show any loss of function under oxidizing or reduced conditions, as 
expected. Successful regain of function for cross-linked (G16C/L38C) was obtained upon 
reversible reduction of the disulfide bond. Taken together, these data demonstrate that the 
hydrophobic core dynamics modulates protease function and support the hypothesis that 
the distal drug resistant mutations, possibly causing drug resistance by modulating 
hydrophobic core dynamics via long range structural perturbations. Since protease 
recognizes and cleaves more than 10 substrates at different rates, our further interest is to 
investigate if there is a differential loss of activity for some specific substrates over the 
others, and whether the order of polypeptide cleavage is somehow affected by restricted 
core mobility. In order to better answer these questions it is essential to understand: what 
determines the substrate binding specificity in protease? A two-pronged approach was 
applied to address this question as described in chapter III and IV respectively. 
In chapter III, I investigated the determinants of substrate specificity in HIV-1 protease 
by using computational positive design and engineered specificity-designed asymmetric 
protease (Pr3, A28S/D30F/G48R) that would preferentially bind to one of its natural 
substrates, RT-RH over two other substrates, p2-NC and CA-p2, respectively. The 
designed protease was expressed, purified and analyzed for changes in structure and 
 ix 
function relative to WT. Kinetic studies on Pr3 showed that the specificity of Pr3 for RT-
RH was increased significantly compared to the wild-type (WT), as predicted by the 
positive design. ITC (Isothermal Titration Calorimetry) studies confirmed the kinetic data 
on RT-RH. Crystal structural of substrate complexes of WT protease and Pr3 variant with 
RT-RH, CA-p2 and p2-NC were further obtained and analyzed. The structural analysis, 
however, only partially confirmed to the positive design due to the inherent structural 
pliability of the protease. Overall, this study supports the positive computational design 
approach as an invaluable tool in facilitating our understanding of complex proteins such 
as HIV 1 protease and also proposes the integration of internal protein flexibility in the 
design algorithms to make the in-silico designs more robust and dependable.  
Chapter IV probed the substrate specificity determining factors in HIV-1protease system 
by focusing on the substrate sequences. Previous studies have demonstrated that three N- 
terminal residues immediate to the scissile bond (P1-P3) are important in determining 
recognition specificity. This work investigated the structural basis of substrate binding to 
the protease. Catalytically active WT protease was crystallized with decameric 
polypeptides corresponding to five of the natural cleavage sites of protease. The 
structural analyses of these complexes revealed distinct P side product bound in all the 
structures, demonstrating the higher binding affinity of N terminal substrate for protease. 
This thesis research successfully establishes that intrinsic hydrophobic core flexibility 
modulates function in HIV-1 protease and proposes a potential mechanism to explain the 
role of non-active site mutations in conferring drug resistance in protease.  Additionally, 
 x 
the work on specificity designed and N terminal product bound protease complexes 
advances our understanding of substrate recognition in HIV protease. 
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CHAPTER I 
INTRODUCTION 
1
  
Since the identification of virus that causes AIDS in 1983-84 (Barre-Sinoussi et al., 1983; 
Broder and Gallo, 1984; Culliton, 1984), substantial progress has been made towards 
understanding the biology of human immunodeficiency virus (Condra et al., 1995) and 
prevention and treatment of AIDS. Detailed biochemical function of each viral 
component, and in many cases macromolecular structure determination of viral and host 
proteins, has helped decipher the key interactions among viral and cellular components 
during the viral replication cycle. This knowledge base, acquired over 30 years of 
research, has led to the development of remarkably effective antiretroviral therapy in 
controlling the progression of AIDS and prolonging patient survival (UNAIDS, 2008). 
Unfortunately, therapy benefits can be compromised by the development of resistance 
towards these drugs (Blanco et al., 2011; Margeridon-Thermet and Shafer, 2010; Rhee et 
al., 2010). Resistance is the consequence of mutations that emerge in the viral proteins 
targeted by anti-retroviral agents. Resistance occurs very rapidly in HIV due to the lack 
of proof-reading mechanism by the reverse transcriptase, rapid replication rate and the 
selective pressures of antiretroviral therapy. HIV often exhibits resistance to several 
classes of anti-retroviral drugs (Shafer et al., 1998) and cross-resistance between drugs 
within a class is very frequent (Hertogs et al., 2000; Miller and Larder, 2001; Rhee et al., 
2010). Consequently, emergence and transmission of drug resistance is a major concern 
that complicates further efforts to control viral replication. 
Currently, there are about 25 drugs targeting different stages in HIV life cycle 
(Menendez-Arias, 2010), including 1) the process of viral fusion to the host cell (fusion 
or entry inhibitors) and 2) viral enzymes: reverse transcriptase, protease and integrase. 
2
  
The enzyme protease cleaves a precursor protein (Gag-Pro-Pol), permitting the final 
assembly of inner core of the viral particles, leading to maturation of virions (Kohl et al., 
1988; Kramer et al., 1986). Only mature virions are infectious. As a result, protease 
inhibitors (PI) are one of the important class of anti-retroviral therapy against HIV. All 
PIs are peptidomimetic compounds that display high affinity for the active site of the 
protease and inhibit the catalytic activity of the enzyme in a highly selective manner. 
However, drug resistance against PIs evolves rapidly in HIV by the selection of 
mutations not only in the active site but also in the regions spatially removed from the 
substrate binding site (Ali et al., 2010; Condra et al., 1995; Gulnik et al., 1995; Kaplan et 
al., 1994; Molla et al., 1996). The drug resistant mutations that occur in direct contact 
with the inhibitor or substrate often disrupt inhibitor binding more than the substrate 
binding and are relatively easier to rationalize (Prabu-Jeyabalan, Nalivaika, and Schiffer, 
2002).  The resistance mutations far away from the active site, however, are harder to 
explain. 
Although, each PI selects for a distinct array of primary mutations, the same co-occuring 
non-active site mutation are often seen for several inhibitors. For example, the distal site 
mutation, A71V, occurs in response to saquinavir (G48R/A71V), atazanavir 
(I50L/A71V) and also amprenavir (I50V/A71V) treatment (Colonno et al., 2004; Molla 
et al., 1996; Roberts, 1995; Skalova et al., 2006). Both G48 and I50 are present in the 
protease flap region and form a part of the ligand-binding site. These observations 
suggested that non-active site mutations mechanistically affect some critical event in 
protease function that is independent of the chemical nature of the inhibitor but, perhaps, 
3
  
associated with its mode of binding. Several explanations have been suggested to explain 
how these non-active site mutations cause susceptibility to resistance. While some studies 
have suggested compensatory roles for these mutations in restoring the activity of 
resistant proteases and viral fitness (Nijhuis et al., 1999), others have implicated their 
importance in maintaining the stability of the resistant proteases (chang and Torbett, 
2010). Some studies support a more dynamic role for these non-active site mutations in 
reducing susceptibility to drugs (Foulkes-Murzycki, Scott, and Schiffer, 2007; Rose, 
Craik, and Stroud, 1998). However, the currently available techniques are unable to view 
the dynamic motions of proteins at nanosecond to second time scales. Therefore, one 
main goal of my thesis research was to experimentally investigate the influence of 
protease flexibility on protease function. Another goal was to establish mechanistic 
correlation between non-active site protease mutations that cause resistance to protease 
inhibitors, and internal protein dynamics that facilitates ligand binding. 
Drug resistance in HIV-1 protease is a state of altered molecular recognition; such that 
mutant proteases still recognize and cleave their natural substrates but no longer bind to 
the inhibitors. Hence, understanding the underlying mechanism of substrate recognition 
in HIV protease is imperative to better discern the preferential ligand binding in resistant 
proteases. To this effect, another goal of my research was to investigate the determinants 
of substrate binding specificity in HIV protease. HIV protease recognizes and cleaves 
more than 12 non-homologous substrates and therefore, has wide substrate specificity. 
Although, there is co-evolution of certain substrates along with drug resistant protease 
mutations (Kolli, Lastere, and Schiffer, 2006; Kolli et al., 2009; Maguire et al., 2002), the 
4
  
majority of the wild type substrates are both recognized and cleaved by different mutant 
variants of HIV protease. While the substrate envelope hypothesis (Prabu-Jeyabalan, 
Nalivaika, and Schiffer, 2002) helps explain how active site resistant variants display 
differential ligand binding, how the substrate recognition is facilitated, when the 
corresponding interacting amino acids are mutated in resistant protease is still unclear. 
Therefore, in this thesis research, I investigated the mechanism of substrate recognition 
by HIV protease using a two-fold approach. First, by computationally identifying and 
biochemically and structurally validating the residues within the protease that facilitate 
substrate recognition, and second, by evaluating the importance of cleavage site residues 
within different substrates, using structural studies.  
In this chapter, I will present the current global perspective on epidemiology, treatment 
and impact of HIV-1/AIDS. I will then briefly describe HIV with a focus on HIV 
protease, mechanism of substrate recognition and emergence of drug resistance against 
protease inhibitors. I will present in detail the work done in understanding the protein 
dynamics in general, and in the context of HIV protease, followed by applications of 
protein design and engineering techniques as used in this thesis research. Finally, I will 
discuss the broader scope of the work presented in this thesis research in furthering our 
understanding of HIV-1/AIDS control and prevention.   
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AIDS: Current global perspective 
Unprecedented commitment to achieve universal access to HIV prevention, treatment, 
care and support for all in need has led to remarkable results in the past decade (WHO, 
2011). The number of new HIV infections has declined by 19% over the past decade 
leveling off the global percentage of adults living with HIV. However, the overall 
number of people living with HIV has steadily increased as new infections occur each 
year, HIV treatments extend life span, and new infections outnumber AIDS death. 
Expanded and improved HIV programs have led to more than 25% decline in HIV 
prevalence among young people aged 15-24 years. Significant reductions in the costs and 
improved access to anti-retroviral therapy has helped bring down the AIDS related 
mortality and improved the quality of life for infected population.   
This progress, however remarkable, is marred by its uneven distribution. Sub-Saharan 
African countries still account for almost 67% of global HIV prevalence. Women account 
for more than half of all people living with HIV worldwide, with nearly 60% of HIV 
infections in Sub-Saharan African countries. HIV infection rates are also increasing in 
Eastern Europe and central Asia. Limiting the spread of HIV requires combining 
behavioral, biomedical and structural HIV preventive interventions, tailored to national 
epidemics across the globe. Developing more effective treatments that are both medically 
improved and available to resource poor countries is a major challenge that remains to be 
overcome. 
 
6
  
Biology of Human Immunodeficiency Virus 
Human Immunodeficiency virus is the causative agent for AIDS. HIV is a single 
stranded, positive sense RNA lentivirus from the retroviridae family (Chiu et al., 1985). 
Lentiviruses characteristically cause long-duration illnesses with long incubation periods. 
Two types of HIVs have been characterized: HIV-1 and HIV-2. HIV-1 is more infectious 
and causes majority of the infections globally. HIV-2 is less infectious (Gilbert et al., 
2003), poorly transmitted in humans and is largely confined to West Africa (Reeves and 
Doms, 2002).  HIV-1 is further divided in several sub-clades with distinct sequence 
differences in the viral proteins. However, clade B is the most predominant in North 
America and hence, is the most widely studied of all HIV-1 clades. 
HIV-1 has 2 copies of single-stranded, positive sense 9.2 kb RNA genome that encodes 
all of the viral proteins, enzymes and adaptor proteins. Due to the intense research efforts 
since the discovery of HIV virus, many aspects of its life cycle are now very well 
understood (Fig I.1). HIV-1 infects cells of human immune system, mainly CD4+ Tcells, 
macrophages and dendritic cells. Upon infection, initial contact is initiated via 
recognition between receptors on viral cell surface and the host cell; leading to the fusion 
of virus with the host cell membrane (Wyatt and Sodroski, 1998). Recent studies have 
shown receptor mediated and non-receptor mediated endocytosis as an alternate 
mechanism for HIV entry in to the host cell (Fackler and Peterlin, 2000; Miyauchi et al., 
2009). Once the virus fuses with the host cell, viral core enters the host cytoplasm, 
undergoes uncoating and forms a reverse transcription complex. Using the host cell 
7
  
machinery and viral protein, reverse transcriptase (RT), the genomic RNA of HIV is 
reverse transcribed to yield minus strand DNA that is then copied into double stranded 
viral DNA (Yarchoan et al., 1985). This process results in frequent mutations in the 
synthesized viral DNA due to the infidelity and lack of proof reading mechanism of RT 
(Bebenek et al., 1989; Perrino et al., 1989; Preston, Poiesz, and Loeb, 1988). As a result, 
the viral population in an infected individual is highly variable, each genome differing by 
one or more mutations. The newly synthesized viral DNA is then transported to the 
nucleus, gets integrated into the host cell genome and is termed provirus. Transport 
across the nuclear membrane is facilitated by several viral proteins (Bukrinsky et al., 
1993a; Bukrinsky et al., 1993b) and integration into the host DNA is catalyzed by viral 
integrase (IN). The integrated provirus can maintain latency (Koup, 2001) to avoid 
detection by the immune system or act as a template for transcription and synthesis of 
viral mRNA. The factors responsible for maintaining latency in the provirus are still 
poorly understood. Some of the full length viral RNAs get spliced (Emerman and Malim, 
1998; Frankel and Young, 1998) and transported to cytoplasm where they get translated 
into viral proteins. These proteins include the structural proteins that form the viral core 
and enzymes that are synthesized as a Gag and Gag-Pro-Pol precursor polyprotein. The 
synthesized proteins and RNA copies of the viral genome then assemble as a virion at the 
cell membrane that subsequently buds from the host cell to give rise to an immature, non-
infectious viral particle (Navia and McKeever, 1990). During or shortly after budding, 
another critical viral protein called protease then cleaves these polyproteins in a regulated 
order (Pettit et al., 2005; Pettit et al., 1998) to generate the full complement of structural 
8
  
proteins including matrix (MA), capsid (CA), nucleocapsid (NC), and the enzymes, 
protease, reverse transcriptase and integrase (Fig I.2). This step is critical for viral 
maturation. Since only mature virions are infectious, protease has been one of the 
important targets for anti-retroviral therapy. 
Targeting different steps in the HIV-1 life cycle has been a key focus in the development 
of better and more effective drugs for the treatment of HIV/AIDS. At present, there are 
thirteen RT inhibitors (RTIs) and nine protease inhibitors (PIs) being successfully used in 
highly effective anti retroviral therapy (HAART). More recently, fusion inhibitors that 
block the entry of virus into the host cell and integrase inhibitors that inhibit the 
integration of viral DNA in the host genome have also been developed. Although, 
HAART has proved to be a potent method for treatment of AIDS and suppression of drug 
resistant strains, resistance remains a permanent threat for patients undergoing retroviral 
therapy. Therefore, the field of drug design against HIV will continue to build on the 
lessons learnt from the current available data and continue to evolve in search of drugs 
with optimized antiviral potency and minimized susceptibility to the emergence of drug 
resistance. 
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Figure I.1.  HIV-1 Life Cycle. Various steps of viral fusion to the host cell: entry, 
reverse transcription, integration, nuclear export, budding and maturation are illustrated. 
Anti-viral drugs currently target steps numbered 1, 3, 4 and 7 respectively.  
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Fig. I.1 
 
 
Image courtesy: National Institute of Allergy and Infectious Diseases 
http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/pages/hivreplicationc
ycle.aspx 
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Figure I.2.  Schematic Representation of HIV-1 Genome and Organization of Gag 
and GagPol Polyproteins. 
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Fig I.2 
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HIV-1 protease 
HIV-1 protease is a 22 Kd homodimeric aspartyl protease essential for viral maturation. 
Protease is required for cleavage of the Gag and Gag-Pro-Pol polyproteins, yielding 
structural proteins and viral enzymes (Kohl et al., 1988) (Fig I.1, Fig I.2 and Fig I.3). 
Protease is a dimer with 99 residues in each monomer. The active site is formed at the 
dimer interface and is comprised of a conserved triad of Asp-Thr-Gly contributed by each 
monomer to form the complete active site (Navia et al., 1989; Wlodawer et al., 1989). 
Out of the three conserved amino acids, Asp is at position 25 and catalyzes the cleavage 
reaction. A general acid-base catalysis mechanism has been proposed (Hyland, 
Tomaszek, and Meek, 1991; Hyland et al., 1991; Silva et al., 1996) based on several 
structural and enzymatic studies. The mechanism involves a water molecule coordinated 
by the catalytic aspartates that is responsible for nucleophilic attack on the carbonyl 
group of the scissile amide bond. One of the catalytic site aspartic acids is suggested to be 
protonated (Adachi et al., 2009) that in turn deprotonates the coordinated water molecule, 
thereby activating this water. The activated water molecule then acts as a nucleophile and 
brings about the substrate cleavage. HIV protease also contains a structural water 
molecule in the active site that forms a bridge between the ligand in the active site and 
residue Ile50 at the flap tips, thereby stabilizing the closed conformation of the enzyme. 
Structurally, protease has been divided into four main regions: the active site (residues 
23-28, 81-84), the flap region (residues 40-60), the dimer interface (residues 1-10, 90-99) 
and the core region (residues 11-22, 29-39, 61-80 and 85-90). Flaps form the roof of the 
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active site and play an indispensible role in ligand binding. The core residues do not 
directly interact with the ligand but are suggested to assist in ligand binding by 
facilitating conformational changes within the core region (Foulkes-Murzycki, Scott, and 
Schiffer, 2007; Rose, Craik, and Stroud, 1998). Therefore, protease is very flexible and 
structural changes occur in regions far away from the active site during catalysis. 
HIV protease has wide substrate specificity. Protease cleaves eleven asymmetric, non-
homologous substrate sites within the Gag, Gag-Pro-Pol polyprotein and the Nef 
precursor protein (de Oliveira et al., 2003). Additionally, at least three auto-proteolytic 
sites (Q7,L33,L63) are also known within the protease (Rose, Salto, and Craik, 1993b). 
The substrate side chains are designated P4 to P1 on the amino-terminal side of the 
scissile bond and P1’ to P4’ on the carboxy terminus (Schechter and Berger, 1967). These 
sites correspond to the substrate binding pockets in the protease: S4-S4’.  Analysis of 
substrate cleavage sites has revealed that protease does not recognize a specific substrate 
sequence (Debouck, 1992; Konvalinka et al., 1990; Pettit et al., 1991; Tozser et al., 
1997a; Tozser et al., 1992; Tozser et al., 2000). Structural studies on HIV-1 protease 
substrate complexes have revealed that protease recognizes a conserved shape or volume 
rather than a particular sequence (Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002) (Fig 
I.4). Although there is no consensus among the sequences of various substrates, the 
hydrogen bond network between protease residues and the backbone atoms of the 
substrates is conserved and this is believed to drive the substrate recognition process. 
Although, the specific determinants of substrate binding specificity in HIV-1 protease are 
still not fully understood, the proteolytic processing of Gag and Gag-Pro-Pol is 
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established to be sequential and highly ordered process (Pettit et al., 2005; Pettit et al., 
1998; Wiegers et al., 1998).  Because this sequential order of substrate cleavage is crucial 
for the virus to mature and maintain fitness and infectivity (Pettit et al., 2002; Pettit et al., 
1994), the complete understanding of the underlying mechanism is pivotal to stopping the 
progression of HIV/AIDS and therefore, an area of active investigation. 
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Fig I.3: Structure of HIV-1 Protease in complex with a substrate. The two monomers 
are shown in cyan and magenta, and the catalytic aspartates are shown in black. In green 
is the substrate peptide. The active site and the flaps are shown in red and gray, 
respectively. 
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Fig. I.3 
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Figure I.4:  The Substrate envelope.  In blue is the consensus volume occupied by at 
least four out of six cleavage site peptides when bound to the D25N inactive HIV-1 
protease.  The six peptides are shown in the same superposition within the consensus 
volume. 
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Figure I.4 
 
 
Reprint from Structure, Vol. 10, Prabu-Jeyabalan, Nalivaika, and Schiffer. Substrate 
shape determines specificity of recognition for HIV-1 protease: analysis of crystal 
structures of six substrate complexes, 369-381, 2002 with permission from Elsevier. 
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Protease inhibitors and Drug resistance 
Inhibitors of HIV-1 protease are designed to block the activity of the enzyme. Various 
design strategies have been used in an effort to design an effective protease inhibitor, 
including: 1) non-peptide active site inhibitors (Moelling et al., 1990; Salto et al., 1994), 
2) dimerization inhibitors (Boggetto and Reboud-Ravaux, 2002) and 3) the transition 
state analogues that include all of the FDA approved protease inhibitors. Efforts have also 
been directed towards development of allosteric inhibitors by targeting regions distal to 
the active site and developing monoclonal antibodies that bind specifically to the non-
active site epitopes on the protease and hinder catalysis (Rezacova et al., 2002). 
However, the transition state analogues have been the most effective in inhibiting 
protease. These are asymmetric peptide mimetics with a central secondary hydroxyl 
group that binds to the catalytic aspartates and mimics the oxygen in the tetrahedral 
transition-state for amide cleavage (De Clercq, 2009; Wlodawer and Vondrasek, 1998).  
Saquinavir (SQV) (Roberts et al., 1990) was the first PI to be approved by the FDA in 
1995. In the 15 years since, eight more highly potent PIs have been approved for 
treatment of AIDS; amprenavir (APV), atazanavir (ATV), darunavir (DRV), indinavir 
(IDV), lopinavir (LPV), nelfinavir (NFV), ritonavir (RTV) and tipranavir (TPV) (Fig I.5). 
With the exception of TPV, all of these PIs mimic the natural substrates of the protease 
and bind competitively within its active site with high specificity and affinity.  
The currently used highly active anti-retroviral therapy (HAART) for the treatment of 
HIV infections involves the administration of a drug cocktail containing two nucleoside 
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analogues and either a PI or a non-nucleoside RTI (Yeni et al., 2002). The use of agents 
from different classes of drugs is instrumental in controlling the development of 
resistance for two reasons. First, multiple mechanisms (each requiring different distinct 
mutations) are required for resistance to occur to all the drugs in a given regimen. 
Second, multiple drugs suppress viral replication more effectively than a single agent 
(Hammer et al., 1997). Therefore, in patients receiving HAART as a first line of therapy, 
emergence of resistance is only possible if there are escape mutants with reduced 
susceptibility to all the drugs in the therapy. Evolving resistant mutations for multiple 
steps in its life cycle could be statistically unfavorable and, therefore, less likely. 
Nevertheless, patient non-compliance and non-adherence can lead to incomplete 
suppression of HIV-1 replication and provide gradual positive selection for the 
emergence of resistant strains. Once resistance develops, a vicious cycle of treatment 
failures and increased levels of resistance begins that severely limits the efficacy of 
currently available drugs in controlling viral replication. 
Remarkable progress has been made in identifying mutations that cause drug resistance 
and understanding the mechanisms by which they do so (Ali et al., 2010; Clavel and 
Hance, 2004) (Tables I.1, I.2 and I.3). These mechanisms differ both for different classes 
of drugs and for the drugs within a given class. As a consequence of the error-prone 
replication by reverse transcriptase, mutations get introduced throughout the transcribed 
genome during viral replication. While these mutations contribute to the genetic diversity 
in wild type HIV population, these can also manifest as amino acid substitutions in all 
HIV drug targets thereby, conferring drug resistance. 
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Resistance to PIs is the consequence of amino acid substitutions that emerge either inside 
the ligand binding cavity of the enzyme, or at the sites distal to the binding pocket 
(Condra et al., 1995; Molla et al., 1996). Mutations that arise within the active site of the 
enzyme directly interfere with inhibitor binding, decreasing the binding affinity of these 
drugs. The mechanism of substrate recognition and cleavage, however, remains 
unaffected in these drug resistant variants and has been elegantly explained by the 
‘Substrate envelope hypothesis’ (King et al., 2004; Prabu-Jeyabalan, Nalivaika, and 
Schiffer, 2002). While primary mutations are usually a signature of particular PIs, cross-
resistance between PIs has also been observed (Table I.3).  
Subsequent to these primary mutations, several secondary or accessory mutations arise 
within the protease further decreasing the sensitivity to PIs (Molla et al., 1996). Often 
these secondary, drug associated mutations are present in domains distal to the active site 
and have been linked to viral fitness and protease stability for mutant strains. Some of 
these mutations are primary drug resistance mutations and others have been suggested to 
contribute to drug resistance when present along with other major mutations. The exact 
mechanism by which these mutations enhance resistance, however, is still only poorly 
understood.  
Of the 99 positions in each monomer, nearly 30 are known to be invariant and 17 
positions are sites of known non-treatment related polymorphisms (Stanford HIV drug 
resistance database; Rhee et al., 2010; Wu et al., 2003). Nearly 45 positions in each 
monomer have been implicated in drug resistance. Of these 45 positions, mutations at 26 
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positions have been shown to significantly decrease susceptibility to one or more PIs and 
others are polymorphic mutations that occur more frequently when associated with 
inhibitor therapy (Velazquez-Campoy, Vega, and Freire, 2002; Wu et al., 2003). 
Furthermore, almost 60% of these 26 positions fall outside the active site region. Thus, 
excluding the invariant positions and including the polymorphic sites associated with 
drug resistance, almost 40-45% of the protease sequence is implicated in conferring drug 
resistance and a staggering 60-63% of the protease sequence has been known to vary in 
patient isolates. 
Various groups, in the past, have studied thermodynamic, structural and kinetic 
parameters of different combinations of some of the major drug resistant mutation and 
contributory or associated non-active site secondary mutations in recombinant protease 
system (Clemente et al., 2004; Liu et al., 2005; Luque et al., 1998; Mahalingam et al., 
2002; Svicher et al., 2005). Almost all these studies have shown that the effect of major 
drug resistance mutation is highly diminished in the absence of paired secondary non-
active site mutations. Although, the mechanism by which these diversely placed non-
active site positions orchestrate altered inhibitor-binding stays largely unknown, some 
residue-specific explanations and suggestions have been put forth. The internal dynamics 
and inherent plasticity of HIV-1 protease (Clemente et al., 2004; Foulkes-Murzycki, 
Scott, and Schiffer, 2007; Piana, Carloni, and Rothlisberger, 2002; Rose, Craik, and 
Stroud, 1998) has been implicated as one of the ways how non-active site mutations may 
induce conformational perturbations in the enzyme altering binding of the inhibitors. 
Kinetic studies conducted on various combinations of active and non-active site protease 
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mutants have shown that many of these protease variants have decreased catalytic 
efficiencies, resulting from either increased Km values or reduced turnover rates or a 
combination of both (Clemente et al., 2004; Shuman et al., 2003). Some mutations, e.g., 
L90M have been shown to make protease a better enzyme for one substrate over the other 
in a clade specific manner (Coman et al., 2008; Shen et al., 2010).  
In this thesis research, I have attempted to experimentally investigate the importance of 
protein flexibility in protease function and the role of non-active site protease mutations 
in contributing to drug resistance.  
 
 
 
 
 
 
 
 
 
25
  
Figure I.5: The chemical structures of nine FDA approved protease inhibitors. 
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Fig I.5 
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Table I.1: Various antiretroviral agents used in the treatment of HIV infection. The 
approved antiretroviral drugs have been listed along with their mechanisms of action and 
the mechanism of evolution of resistance against them. 
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Table I.1 
Drugs Mechanism of Action Mechanism of Resistance 
Nucleoside analogues 
Zidovudine 
Stavudine 
Lamivudine 
Didanosine 
Zalcitabine 
Abacavir 
Analogues of normal nucleosides 
 
Active as triphosphate derivatives 
 
Incorporated into nascent viral DNA 
 
Premature terminate HIV DNA 
synthesis 
Thymidine analogue mutations 
promote ATP-mediated and 
pyrophosphate-mediated excision of 
the incorporated terminator 
 
M184V or Q151M complex 
mutations impair incorporation of 
nucleoside analogues. 
 
Nucleotide analogues 
Tenofovir 
Same as nucloside analogues K65R impairs incorporation of 
tenofovir into DNA 
 
Thymidine analogue mutations often 
associated with cross-resistance to 
tenofovir 
 
Nonnucleoside 
reverse-transcriptase 
inhibitors 
Nevirapine 
Efavirenz 
Delavirdine 
 
Bind a hydrophobic pocket of HIV type 
1 reverse transcriptase 
 
Block polymerization of viral DNA 
 
Inactive against HIV type 2 
 
Mutations reduce affinity of the 
inhibitors for the enzyme 
 
Single mutations generally sufficient 
to induce high level of resistance 
Protease Inhibitor 
Saquinavir 
Ritonavir 
Indinavir 
Nelfinavir 
Amprenavir 
Lopinavir 
 
Structure derived form natural peptidic 
substrates of the HIV type 1 protease 
 
Bind the active site of the protease 
Mutations reduce affinity of the 
inhibitors for the enzyme 
 
High-level resistance requires 
accumulation of mutations 
Fusion inhibitors 
Enfuvirtide 
36 amino acid peptide derived from the 
HR2 domain of glycoprotein 41 
 
Interferes with glycoprotein 41-
dependent membrane fusion 
 
Mutations affect HR1, a domain of 
glycoprotein 41 whose interaction 
with HR2 promotes membrane fusion 
Adapted with permission from N Engl J Med 2004, 350:1023-1035, François Clavel, 
M.D., and Allan J. Hance, M.D. HIV drug resistance. 
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Table I.2: Reverse transcriptase mutations involved in resistance to HIV to different 
classes of drugs. 
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Table I.2 
 
 
Reprinted with permission from N Engl J Med 2004, 350:1023-1035, François Clavel, 
M.D., and Allan J. Hance, M.D. HIV drug resistance. 
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Table I.3: Protease and gag mutations involved in resistance to HIV to different 
classes of drugs. 
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Table I.3 
 
 
 
Reprinted with permission from N Engl J Med 2004, 350:1023-1035, François Clavel, 
M.D., and Allan J. Hance, M.D. HIV drug resistance. 
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Protein dynamics 
Conformational dynamics are important in regulating protein function (Eisenmesser et 
al., 2005; Kern and Zuiderweg, 2003). The textbook mechanistic explanation for 
molecular recognition by Koshland: ‘Induced fit hypothesis’ (Koshland, 1958) proposed 
that the conformational differences between the free and ligand bound states of an 
enzyme are the result of binding interactions driving the protein towards a new 
conformation which is more complementary to its binding partner. This hypothesis was 
based on the assumption that the protein exists in a single stable conformation, under the 
given experimental conditions. However, recent studies have shown that proteins are 
inherently dynamic and sample a vast number of conformations (Boehr, Nussinov, and 
Wright, 2009). Along with the lowest energy native conformation, other thermally 
accessible conformational substates may play important roles in molecular recognition 
(Frauenfelder, Sligar, and Wolynes, 1991).  Thus, the current understanding of the role of 
dynamics in enzyme function has expanded to support that a conformational 
heterogeneity exists in solution, and the ligand select the most favored conformation 
(Boehr, Nussinov, and Wright, 2009). Such conformational selection has been observed 
for several enzymes, including ribonuclease A (Beach et al., 2005), adenylate kinase 
(Henzler-Wildman et al., 2007; Wolf-Watz et al., 2004) and dihydrofolate reductase 
(Boehr et al., 2006). While molecular dynamic simulation studies (Keskin, 2007; Tobi 
and Bahar, 2005) have suggested the existence of different conformational ensembles of 
free protein, structural characterization of conformations other than the one most 
populated in the crystals has been very challenging. NMR and other single molecule 
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spectroscopic techniques, however, have helped further our understanding of these 
dynamic processes and steady state conformational heterogeneity of proteins in solution 
(Busenlehner and Armstrong, 2005; Palmer, 2001; Parak, 2003).  
Conformational flexibility in HIV-1 protease has been linked to not only its function but 
also to the development of drug resistance (Foulkes-Murzycki, Scott, and Schiffer, 2007; 
Rose, Craik, and Stroud, 1998). Other than the prominent flap dynamics that allows 
access and binding to the substrates, the characterization of subtle core dynamics has 
been challenging. Drug resistant mutations in protease occur within the active site as well 
as non-active distal sites (Ali et al., 2010; Muzammil, Ross, and Freire, 2003). This 
structural distribution of resistance mutations remote from the active site is not random 
and is now believed to bring about their effect by modulating the structural and dynamic 
diversity in HIV -1 protease. These mutations perhaps, generate novel conformational 
heterogeneity in the protease molecules in solution, such that there is a preferential 
selection for the conformers that bind substrates over inhibitors. This change in protein 
population represents a general mechanism for protein function that interconnects 
molecular recognition, protein regulation and resistance. The experimental information 
presented in chapter II, investigates the requirement of protein dynamics in protease 
function. 
Nonetheless, deciphering the dynamic heterogeneity in proteins is not straightforward. 
Not all conformations in an ensemble are likely to be equally ‘druggable’ because of the 
key differences in the energetics and/or accessibility of the active site in different 
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members of the conformational ensemble. Therefore, advanced computational methods 
are required to explore this vast conformational space and provide alternative strategy for 
understanding drug resistance by incorporating the conformational ensemble in the drug 
design. Applying advanced computational methods could potentially aid greatly in design 
of protein function and engineering of new enzymes (Jiang et al., 2008; Rothlisberger et 
al., 2008).  
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Protein design and engineering 
Despite remarkable successes, initial attempts in creating artificial enzymes and catalytic 
antibodies have resulted in relatively poor catalysts, compared to the naturally occurring 
enzymes (Hilvert, 2000; Jiang et al., 2008). However, combining computational design 
with in vitro evolution, a newly engineered enzyme has been created and selected for, 
with activity similar to the naturally occurring enzyme (Rothlisberger et al., 2008). These 
results show that a synergistic approach combining the computational design with in vitro 
evolution can yield effective biocatalysts. Unfortunately, not all mutations introduced by 
evolution can be readily explained. This could be because we do not completely 
understand the conformational changes involved in substrate recognition, formation of 
transition-state complexes and product release. The predictive potential of computational 
techniques could be utilized to better understand the intrinsic fluctuations of a protein and 
the conformational changes that bring about molecular recognition. To this effect, as a 
part of this thesis research, we have used computational protein design to better 
understand the process of substrate recognition by HIV-1 protease. Once the determinants 
of substrate binding specificity to protease are deciphered, this knowledge could permit 
the design of better therapeutics less likely to induce resistance. More generally, having a 
handle on the role played by dynamic conformational ensembles in protein function could 
lead to the design and engineering of de novo enzymes with novel functions. 
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Scope of thesis 
Drug resistance continues to be a significant obstacle in the treatment of HIV/AIDS 
infection. Better understanding of various aspects of viral life cycle and viral proteins 
used as drug targets is essential to designing better and robust drugs less susceptible to 
resistance. While HIV-1 protease is one of the successfully targeted viral enzymes, the 
details of its mechanism of action are still poorly understood. Resistance mutations in 
protease are structurally distributed over the entire secondary structure. Where the 
mutations along the active site directly interfere with inhibitor binding, the role of non-
active site mutations in contributing to drug resistance is still unclear. The current 
knowledge on how the resistant proteases maintain their ability to recognize and cleave 
their natural substrates is also very limited. The intrinsic dynamics of protease is 
suggested to facilitate these events of substrate recognition and cleavage in both the WT 
protease and the resistant variants. The thesis research presented here demonstrates that 
the core dynamics in HIV protease is important in modulating protease function. This 
work further hypothesizes that there exists a conformational heterogeneity in the 
conformational space that an unliganded protease can sample and therefore, the non-
active site mutations possibly select for a different native conformation in preserving 
substrate recognition over inhibitor binding. Protease has wide substrate specificity and 
focusing on how this specificity is determined could be pivotal in understanding the 
altered molecular recognition of the resistant proteases. Computational design approach 
in combination with structural-biochemistry tools could immensely enhance our 
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understanding of the molecular basis of substrate recognition. This knowledge in turn, 
would lead to development of better drugs less likely to develop resistance.  
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ABSTRACT 
Human immunodeficiency virus Type-1 (HIV-1) protease is crucial for viral maturation 
and infectivity. Studies of protease dynamics suggest that the rearrangement of the 
hydrophobic core is essential for enzyme activity. Many mutations in the hydrophobic 
core are also associated with drug resistance and may modulate the core flexibility. To 
test the role of flexibility in protease activity, pairs of cysteines were introduced at the 
interfaces of flexible regions remote from the active site. Disulfide bond formation was 
confirmed by crystal structures and by alkylation of free cysteines and mass 
spectrometry. Oxidized and reduced crystal structures of these variants show the overall 
structure of the protease is retained. However, cross-linking the cysteines led to drastic 
loss in enzyme activity, which was regained upon reducing the disulfide cross-links. 
Molecular dynamics simulations showed that altered dynamics propagated throughout the 
enzyme from the engineered disulfide. Thus, altered flexibility within the hydrophobic 
core can modulate HIV-1 protease activity, supporting the hypothesis that drug resistant 
mutations distal from active site can alter the balance between substrate turnover and 
inhibitor binding by modulating enzyme activity.  
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INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-1) protease is a homodimeric, aspartyl 
protease with 99 residues in each monomer. Protease is essential for post-translational 
processing of the viral polyprotein Gag-Pro-Pol during the assembly and maturation of 
viral particles (Kohl et al., 1988; Kramer et al., 1986). There is an internal two-fold 
symmetry in the protease dimer. However, ligands are asymmetric and introduce 
asymmetry in the dimer upon binding. Under protease inhibitor (PI) therapy, drug 
resistance mutations arise within the active site of the enzyme. These active site 
mutations directly interfere with inhibitor binding and are primary cause of drug 
resistance to PIs. Additional mutations occur throughout the enzyme, and although they 
have often been shown to contribute to drug resistance (Clemente et al., 2004; 
Muzammil, Ross, and Freire, 2003; Ohtaka, Schon, and Freire, 2003), the mechanism by 
which they do so is poorly understood. 
Ligand binding in protease involves conformational changes in the protease flaps and the 
hydrophobic core residues. While the flaps of the unliganded protease are highly dynamic 
(Freedberg et al., 2002; Galiano, Bonora, and Fanucci, 2007; Ishima et al., 1999; Ishima 
and Louis, 2008; Perryman, Lin, and McCammon, 2004; Perryman, Lin, and 
McCammon, 2006) and exhibit large conformational changes during ligand binding, 
hydrophobic core regions also exhibit subtle conformational changes (Foulkes-Murzycki, 
Scott, and Schiffer, 2007). Of the 19 residues that comprise the hydrophobic core of HIV-
1 protease in each monomer, 13 sites are associated with drug resistance (Foulkes-
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Murzycki, Scott, and Schiffer, 2007) (Figure. II.1). The role of these core residues, which 
do not contact either substrates or inhibitors directly, in substrate binding or drug 
resistance is not obvious and remains largely unexplored. Molecular dynamic simulations 
on unliganded HIV protease suggested the conformational changes occurring during side 
chain repacking in the hydrophobic core or “Hydrophobic sliding” as possible 
mechanism affecting drug susceptibility (Foulkes-Murzycki, Scott, and Schiffer, 2007). 
The hydrophobic core domains of each protease monomer rearranges through correlated 
sliding motions facilitated by near-isoenergetic exchange of van der Waals contacts 
between hydrophobic side chains such that the hydrogen bonding network within the 
core, primarily with the backbone, is conserved. While these simulations indicate that the 
rearrangement of the core facilitates conformational changes in the protease, much 
remains unknown about the role of this rearrangement in catalytic function and drug 
resistance. 
The contributions of protein dynamics in both protein structure and function have been 
investigated in other systems. Studies on the multidrug efflux pump AcrB (Seeger et al., 
2008) and caspase7 (Witkowski and Hardy, 2009) have shown the functional importance 
of flexible regions, but there has been little emphasis on studying the dynamics of the 
hydrophobic core of the proteins. The reasons are two fold: 1) difficulty in accessing the 
hydrophobic core in folded proteins and, 2) limited resolution of currently available 
experimental techniques to view protein dynamics. While NMR, Mass spectrometry and 
other single molecule techniques have furthered our understanding of protein dynamics 
and conformational heterogeneity of proteins in bulk solution (Blackburn, Veloro, and 
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Fanucci, 2009; Busenlehner and Armstrong, 2005; Palmer, 2001; Parak, 2003), structural 
characterization of conformations other than those found in the crystal structures, remains 
challenging. 
We experimentally investigated the role of hydrophobic core flexibility in HIV-1 protease 
function using site-directed cysteine cross-linking. Disulfide bonds are usually either 
structural and stabilize a protein or catalytic and modulate the function of proteins 
involved in cellular pathways (Brandes, Schmitt, and Jakob, 2009; Schmidt, Ho, and 
Hogg, 2006; Spadaro et al.; Thornton, 1981). Disulfide bonds which modulate activity 
are both useful in functional description of proteins and provide a method to evaluate the 
regulation of function in proteins (Bass et al., 2007; Lazear et al., 2008; Seeger et al., 
2008). In this study, site-directed cysteine cross-linking provided evidence for the 
requirement of conformational changes in the hydrophobic core of HIV-1 protease for 
efficient cleavage of its substrates. The reversibility of disulfide chemistry worked as a 
molecular switch to modulate protease activity confirming that cross-linking caused the 
reduced activity (Figure. II.2). These results confirm the role of hydrophobic core 
flexibility in protease function. 
Since conformational flexibility in HIV-1 protease has also been implicated in drug 
resistance (Foulkes-Murzycki, Scott, and Schiffer, 2007; Galiano et al., 2009; Rose, 
Craik, and Stroud, 1998), we hypothesize that the non-active site mutations may generate 
novel conformational heterogeneity in the protease, such that there is a preferential 
selection for conformers that process substrates than bind inhibitors.  Therefore, intrinsic 
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protein dynamics can mechanistically connect protein function, molecular recognition 
and drug resistance. More generally, hydrophobic core rearrangement may represent a 
mechanism by which proteins undergo the necessary conformational changes required for 
function. 
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Figure II.1. Drug resistance mutations in HIV-1 protease. Active site and the primary 
active site residues causing drug resistance (D30N, G48V,I50L/V, V82A/F/T, I84V) are 
colored in red. Hydrophobic core residues associated with drug resistance (I13V, I15V, 
L24I, L33F, M36I, I62V, I64V, I66F, V77I, I85V, L89M, L90M, I93L) are colored cyan. 
Remaining hydrophobic core residues  and rest of the protease are in yellow and gray, 
respectively. Catalytic Asps and the loops containing residues 11-22, 31-38 and 58-78 are 
displayed in black.   
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Fig. II.1 
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Figure II.2. Schematic of cysteine redox chemistry used in this study. The cysteine 
substituted and non-cross-linked protease is flexible and as active as WT enzyme. Upon 
oxidation of cys-teines, protease gets cross-linked via disulfide bond. Resulting loss of 
hydrophobic core flexibility is accompanied by loss of catalytic activity that is reversible 
upon reduction of the disulfide bond. 
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Fig II.2 
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RESULTS 
Rationale for cysteine engineering and chosen cysteine pairs  
Analysis of previous MD simulations (Foulkes-Murzycki, Scott, and Schiffer, 2007) 
revealed that 19 core residues in each protease monomer had limited solvent accessibility 
throughout the 14 ns simulations (Figure  II.1). During the simulations these hydrophobic 
core residues undergo conformational changes concurrent with the opening of the active 
site cavity.  We hypothesized that this hydrophobic sliding in HIV-1 protease are critical 
for proteolytic activity. To test this hypothesis, specific pairs of cysteines were introduced 
into the protease in a cysteine free background. MD simulation trajectories (Foulkes-
Murzycki, Scott, and Schiffer, 2007) were analyzed at various time points during the 
simulations and cysteine pairs were chosen at protease positions to restrict the movement 
of the hydrophobic domains using the Cβ-Cβ distance criterion for allowing disulfide 
bond formation (Hazes and Dijkstra, 1988) (Table II.1). The selection of residue 
positions was based on their proximity to the rearranging hydrophobic core and was not 
limited to the 19 positions comprising the core. Three distinct regions containing residues 
(11-21), (31-38) and (58-78) were seen to be tethered to the core and exhibit extensive 
rearrangement. Specifically, G16, R14 and E65 residues, although not hydrophobic 
themselves, are contiguous with the hydrophobic core and along with L38 met the 
distance criteria. These solvent accessible sites were chosen as suitable to probe the 
hydrophobic core dynamics and are amenable to reduction-oxidation chemistry. Under 
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appropriate oxidation conditions, the introduced cysteines should form disulfide cross-
links, likely restricting hydrophobic core movement and potentially enzymatic activity. 
Two protease variants, each with a unique cysteine pair, were constructed (Figure II.3a). 
The first pair (G16C/L38C) would establish an intra-monomeric cross-link that should 
severely restrict hydrophobic core rearrangements. An alanine control variant 
G16A/L38A was generated to ensure that these sites could tolerate substitutions without 
compromising protease activity. The second cysteine pair (R14C/E65C) was designed as 
a control to form cross-links at sites that should not restrict hydrophobic core 
rearrangements, as the relative distance between these residues did not significantly 
change during the simulations (Foulkes-Murzycki, Scott, and Schiffer, 2007) (Table II.1). 
Cross-linking in both these variants should occur under oxidizing conditions, but loss of 
protease function was predicted, based on our hypothesis, in only the G16C/L38C 
variant. Cross-linking in G16C/L38C should restrict the hydrophobic core dynamics and 
hinder activity. In R14C/E65C variant, protease function should be unaffected under both 
oxidizing and reducing (cross-linked (oo) and non-cross-linked (rr)) conditions because 
core rearrangements should be unaffected (Figure II.2). 
Modulation of protease activity 
By exploiting the reversibility of disulfide bonding, the effect of restricted flexibility on 
protease function was evaluated. Protease mediated cleavage of a fluorogenic peptide 
substrate derived from the native CA-p2 cleavage site on Gag polyprotein was measured 
in the presence and absence of reducing agent. The WT, (G16C/L38C)rr, 
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(G16A/L38A)ctrl, and (R14C/E65C)rr proteases all showed similar catalytic activity 
(Table II.2). In contrast, the cross-linked protease (G16C/L38C)oo showed 146-fold lower 
activity than the non-cross-linked (G16C/L38C)rr, demonstrating dramatic loss of 
function. 70% of this function was recovered upon addition of the reducing agent TCEP, 
demonstrating that the loss of activity was due to the G16C/L38C disulfide bond. The 
R14C/E65C variant exhibited comparable catalytic activity under both oxidizing and 
reducing conditions, as expected. These results confirm that the activity of disulfide-
crosslinked variants depends on the location of the cross-link. Protease activity was only 
sensitive to the cross-link that restricted the flexibility of HIV-1 protease hydrophobic 
core. 
Structural analysis  
Six crystal structures of the engineered protease variants were determined (Table II.3). 
Five structures were in complex with DRV, a 4 pM inhibitor of WT (Surleraux et al., 
2005), including the oxidized and reduced forms of G16C/L38C, reduced R14C/E65C, 
WT and G16A/L38A. The final structure was an apo structure of the oxidized 
G16C/L38C variant.  In the oxidized G16C/L38C variant in complex with DRV, perhaps 
due to the high affinity of DRV and/or the asymmetry of the crystal packing, although 
contiguous electron density is observed, one of the disulfide bridges is in a highly 
strained geometry. However, in the apo form of G16C/L38C variant both disulfides are 
clearly observed, (Figure II.4) although this structure was excluded from all comparative 
structural analyses because of the relatively low resolution. 
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The overall structural fold of all cysteine substituted protease complexes was well 
preserved when compared to the WT, with RMSD ranging from 0.06 to 0.09 (Figure. 
II.3b and c). Hydrogen bond analysis revealed that all structurally important hydrogen 
bonds were conserved for all DRV complexes confirming that the known mode of ligand 
binding was intact in these proteases. The disulfide bonds observed in DRV(G16C/L38C)or 
and apo(G16C/L38C)oo structures fall  into geometric categories (-RHHook and –LHHook 
respectively) commonly observed in natural proteins (Schmidt, Ho, and Hogg, 2006). 
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Table II.1. Cβ- Cβ distance between the cysteines modeled at sites (G16, L38) and 
(R14, E65) at 0 ns, 10 ns and 14.5 ns MD simulation snapshots (Foulkes-Murzycki, 
Scott, and Schiffer, 2007) 
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Table II.1 
 Cβ- Cβ distance (Å) 
 0 ns 10 ns 14.5 ns 
G16-L38 5.71 4.67 2.99 
R14-E65 4.32 4.68 4.79 
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Table II.2. Kinetic values of substrate cleavage for the WT, cross-linked, non-cross-
linked variants of G16C/L38C and R14C/E65C and G16A/L38A variants of HIV-1 
protease. 
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Table II.2 
Protease Variants Catalytic Activity, kcat/KM (µm−1s−1) 
Wild-type 6.8x10-2 ± 0.002 
G16C/L38C (rr) 7.6 x10-2 ± 0.004 
G16C/L38C (oo) 5.2 x10-4 ± 2.5E-6 
G16C/L38C(oo) + 5mM TCEP 
(regain of function) 
4.7 x10-2 ± 0.006 
G16A/G38A 6.2 x10-2 ± 0.002 
R14C/E65C (rr) 6.5 x10-2 ± 0.003 
R14C/E65C (oo) 7.1 x10-2 ± 0.004 
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Table II.3. Crystallographic statistics for DRV complexes of WT, G16C/L38C (or, 
rr), R14C/E65C (rr), G16A/L38A and apo G16C/L38C (oo) HIV-1 proteases. 
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Table II.3 
Variable DRV-WT 
DRV-
G16C/L38C 
(rr) 
DRV-
G16C/L38C 
(or) 
DRV-
G16A/L38A 
Ala (control) 
Apo- 
G16C/L38C 
(oo) 
DRV-
R14C/E65C 
(rr) 
Resolution, Å 1.5 1.95 1.3 1.9 2.8 1.8 
Temperature, 
°K 
100 100 100 100 100 100 
Space group p212121 p212121 p212121 p212121 p212121 p212121 
Unit cell 
parameters 
      
a, Å 50.9 50.9 51.24 51.1 51.47 50.7 
b, Å 57.8 57.9 58.5 59.4 58.16 57.9 
c, Å 61.6 61.9 61.8 62.2 61.04 61.5 
Z 4 4 4 4 4 4 
Rmerge, % 4.6 7.3 7.6 6.8 9.8 7.1 
Completeness, 
% 
92.2 96.3 92.4 99.4 97.9 99 
Total reflections 195859 92311 331698 110382 31353 120045 
Unique 
reflections 
27531 13469 42908 33665 5552 17513 
I/σ 15.1 10.4 18.3 14.7 8.1 10.8 
RMSD, Å       
Bond length, Å .010 .009 .008 .011 .020 .012 
Bond angles 1.38 1.31 1.37 1.44 1.6 1.46 
Rfactor, % 16.6 18.3 18.4 17.9 25.6 17.89 
Rfree, % 19.2 24.2 19.9 23.5 30.2 22.50 
Redundancy, % 7.1 6.9 7.7 3.3 5.7 6.9 
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Figure II.3. Structural analysis of protease with engineered cysteines. (a) Sites for 
engineering cysteines in HIV-1 protease are shown with backbone Cα (G16C/L38C) in 
red and (R14C/E65C) in blue. (b) The backbone structural superposition of DRV 
complexes of (G16C/L38C)rr and (R14C/E65C)rr on WT in black. Under reducing 
conditions, no disulfide bonds were observed. Alternate conformations for cysteine side 
chains were, however, seen for 50% of substituted cysteines in each pair analyzed. (c) 
apo(G16C/L38C)oo with disulfide bonds on both sides of the dimer shown in orange color. 
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Fig II.3 
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Figure II.4: Electron density maps showing the disulfide bonds in both monomers of 
apo(G16C/L38C)oo contoured at 1σ  
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Fig. II.4 
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Molecular dynamic simulation analysis of cross-linked and non-crosslinked 
structures.  
To evaluate the ability of engineered cross-links to restrict hydrophobic core dynamics, 
MD simulations were carried out for 20 ns on the cross-linked and non-crossliked 
protease.  DRV was removed from the starting structures, DRV(G16C/L38C)rr and a model 
of  DRV(G16C/L38C)oo. Extensive structural differences were observed in the protease 
backbone for the (oo) and (rr) struc-tures of G16C/L38C protease between 0 ns and 20 ns 
(Figure. II.5). These differences map to backbone shifts of greater than 1Å and are most 
pronounced for the protease flaps (residues 45-55) as indicated by the double difference 
plots. The presence of disulfide bonds restrained the enzyme in (G16C/L38C)oo, leading 
the flaps to open after 20 ns. In comparison, for the (G16C/L38C)rr simulation, the 
unrestricted hydrophobic core region showed subtle motions, with no significant motion 
elsewhere in the protease dimer on the time scale of these simulations. This suggests that 
flap movements can be modulated in response to the restricted hydrophobic core 
dynamics as caused by the formation of a disulfide between G16C and L38C. 
The structural regions containing residues (11-21), (31-38) and (58-78) that were 
previously implicated in the hydrophobic core sliding (Foulkes-Murzycki, Scott, and 
Schiffer, 2007) (Figure II.1) were further analyzed for the effect of physical 16C/38C 
cross-linking on the side chain conformational rearrangement in the core during the MD 
simulations. While quantifying the restricted sliding is challenging, structural analysis of 
MD trajectories at various time points revealed that side chain repacking within the 
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hydrophobic core was restricted in the (G16C/L38C)oo simulations compared to the 
(G16C/L38C)rr simulations. In (G16C/L38C)rr simulations, the hydrophobic core side 
chains sampled a variety of conformations, exchanging van der Waals contacts with 
neighboring residues. However in the (G16C/L38C)oo simulations, most of the 
hydrophobic core interactions were maintained. These results suggest that the restricted 
hydrophobic core dynamics observed in (G16C/L38C)oo  simulations is a direct 
consequence of disulfide cross-linking and likely impairs catalysis. 
Conclusions  
In this study site-directed cysteine engineering was used to reversibly restrict the internal 
dynamics in protease and evaluate the effects on function. The double-cysteine mutant 
(G16C/L38C) was selected as a pivotal pair of residues that varied significantly in 
separation distance depending on the conformational state of the protein. Thus cross 
linking them would severely restrict the internal core dynamics.  The double-cysteine 
mutant (R14C/E65C) was used as internal controls, as these residues, though on separate 
loops, were not seen to change their separation distance significantly. Reduction-
oxidation of the disulfide bridges was used as a switch to regulate hydrophobic core 
dynamics and eventually protease function (Figure. II.2). The formation of disulfide 
(G16C/L38C) cross-links in fact exerted conformational restraints on the hydrophobic 
core, compromising protease activity. This mechanism of core rearrangement explains 
the results in the observed inactivation of (G16C/L38C)oo that was largely restored upon 
reversing the disulfide bonds to (G16C/L38C)rr (Table II.2). Activity was lost and 
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regained only in the (G16C/L38C) variant, where hydrophobic core movements were 
expected to be crucial for protease function. In the control case of (R14C/E65C) variant 
crosslinking did not alter enzyme activity. These results strongly support the mechanistic 
role of hydrophobic core rearrangement in protease function.  
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Figure II.5. Molecular dynamics simulation analyses. Differences in internal Cα-Cα 
distances between the 0ns and 20ns snapshots of the cross-linked (oo) and non-
crosslinked (rr) forms of (G16C/L38C) variant are shown in the double difference plots. 
Each contour line represents a deviation by 0.5Å. Black, green, blue and red distinguish 
the contour ranges -1.0 Å and below, -1.0 to -0.5 Å, 0.5-1.0 Å and 1 Å and above, 
respectively. (a) Backbone superposition of (G16C/L38C)oo from 0ns (cyan) and at 20ns 
(pale cyan). (b) Backbone superposition of (G16C/L38C)rr from 0ns (light pink) to 20ns 
(magenta) in MD simulations. The side chains of active site aspartic acids and the 
engineered cysteines are displayed. 
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Fig II.5 
 
 
 
 
 
 
 
(a) (G16C/L38C)oo (b) (G16C/L38C)oo 
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DISCUSSION 
 
HIV-1 protease undergoes large conformational changes to bind ligands. We show that 
conformational changes are essential to protease activity. Flap motion and hydrophobic 
core repacking have been previously implicated as putative determinants in protease 
activity; however, due to the inherent challenges of manipulating protein dynamics, had 
never been experimentally tested. Our experimental findings provide strong support that 
hydrophobic core flexibility contributes to the efficiency of substrate cleavage by HIV-1 
protease. 
When HIV protease processes substrates, the enzyme undergoes large conformational 
changes upon substrate recognition, cleavage and product release. Competitive active site 
inhibitors, lock down these conformational changes by tightly binding to the active site of 
the enzyme, mimicking a transition state. Drug resistance occurs when the balance 
between substrate recognition and turnover and inhibitor binding is perturbed. In the case 
of the active site, resistance-conferring mutations occur in such a manner that directly 
preserves substrate recognition and turnover while compromising inhibitor binding 
(Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002). However many mutations associated 
with resistance occur outside the active site within the protease hydrophobic core 
(Clemente et al., 2004; Foulkes-Murzycki, Scott, and Schiffer, 2007; Muzammil, Ross, 
and Freire, 2003; Rhee et al., 2010) (Figure II.1). Mutations that modulate the dynamics 
of the hydrophobic core of HIV-1 could modulate the functional properties of the active 
site, and thus the relative binding affinities for substrates and inhibitors. We hypothesize 
that distal mutations outside the active site cause drug resistance when the balance 
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between substrate recognition and turnover, a dynamic process, and inhibitor binding, a 
locking down of the enzyme, is altered in a manner to favor substrate turnover by 
modulating the flexibility of the core of HIV-1 protease.  
This study demonstrates the essential role of the hydrophobic core in modulating enzyme 
activity. The use of specific cross-links to probe the impact of dynamics in protease 
activity provides a new tool, when combined with MD simulations, to investigate the 
effects of mutations distal from active site on hydrophobic sliding and drug resistance. In 
summary, our data provides evidence to support that hydrophobic core flexibility 
modulates enzyme activity in HIV-1 protease, and also proposes a novel mechanism for 
the role of non-active-site mutations in the development of drug resistance. 
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MATERIALS AND METHODS 
Nomenclature for structural and molecular dynamic simulation studies 
We determined six crystal structures and developed the following nomenclature to serve 
as concise references. Inhibitors when present are indicated with a subscript prefix 
followed by the cysteine mutations and a subscript suffix indicates the oxidation state of 
each protease monomer. Thus, DRV(G16C/L38C)rr refers to DRV complexed with the 
G16C/L38C variant where the introduced cysteines are in their reduced state in both 
monomers. The rr could be replaced with oo for crosslinked/oxidized or by or for mixed 
population of reduced and oxidized forms of the two monomers in the protease. 
Detection of Cross-links 
 Cross-linking of cysteines was monitored by quantifying free sulfhydryl content by 
Ellman’s test (Baldwin et al., 1995; Ellman, 1959; Scientific, 22582) and further verified 
by alkylation of cysteines and mass spectrometry (Seeger et al., 2008). For Ellman’s test, 
under reducing conditions, detection of four molecules of free sulfhydryls per protease 
dimer in both variants (G16C/L38C and R14C/E65C) confirmed the absence of disulfide 
bonds. Oxidizing conditions, however, yielded no Ellman’s reaction, indicating the 
absence of reduced sulfhydryls in the two oxidized samples, confirming complete cross-
linking. As positive and negative controls for quantifying sulfhydryls, bovine serum 
albumin (BSA, containing one free cysteine) and the G16A/L38A variant (contains no 
cysteine), respectively, were assayed by Ellman’s test. Determination of the crystal 
structures of the designed variants further verified these results. 
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The presence of disulfide bond in (G16C/L38C)oo protein preparation was further 
confirmed by using maleimides; NEM (N-ethyl maleimide) and NMM (N-methyl 
maleimide) as thiol modifying agents followed by molecular weight detemination using 
mass spectrometry. Maleimides readily react with the thiol group found on cysteine to 
form a stable carbon-sulfur bond. DTT (Dithiothreitol) was used as a reducing agent. 
Protein samples for WT and (G16C/L38C)oo were prepared in 0.1M sodium phosphate 
buffer pH 7.0. All reagents including maleimides and DTT were prepared in 0.1M PBS 
pH7.0. 10ug of protein (38ml) was diluted with 0.1M PBS (19ml) followed by 5ml of 
63mM NEM (5mM final concentration). The reaction was left at RT for 1.5hr to ensure 
complete alkylation. Only those cysteines that are not involved in disulfide bond will be 
available for alkylation. 5ml of 205.5mM DTT (15mM final concentration) was then 
added to this reaction mixture and the reaction was heated at 60°C for 30min. Finally, in 
the second step of alkylation, 20ml of 199.1mM (45mM final concentration) NEM was 
added and the reaction was incubated at RT for 1.5hr to alkylate the cysteines made 
available upon reduction by DTT. The reverse procedure (NMM followed by DTT 
followed by NEM) was also performed at the same concentrations mentioned above. 5ml 
of this reaction was injected in PLRPS column and washed at 5ml/minute for 10 minutes 
in 95% of 0.1% Formic acid. The column was further washed at 3 ml/minute with a 
gradient of 0.1% formic acid in acetonitrile at the following concentrations: 5%( 1 mint) 
to 60% (2mints) to 95% (2.5mints) and finally 5% (2.5 mints.) and resulting spectra 
analyzed. The MS method was to scan from m/z 400-2000 for 10min in + V mode with 1 
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sec scans and a lockmass scan every 10seconds. The data was deconvoluted with the 
Maxent software (Ferrige et al., 1991). 
The results demonstrate that no alkylation was detected after the first alkylation reaction 
(Figure II.6). However, the second alkylation following reduction of disulfides upon 
treatment with DTT resulted in mass spectra consistent with the additive molecular 
weight of protease monomer alkylated with two molecules of NMM. These results 
confirm that the engineered cysteines in (G1C/L38C)oo protein sample were completely 
oxidized and therefore, unavailable for reaction with NEM. Treatment with DTT resulted 
in reduction of disulfide bond, thereby making two cysteines in each monomer available 
for reaction with NMM. A small fraction of N-terminal alkylation was also detected in 
(G1C/L38C)oo sample. These values were consistent with the N terminal alkylation 
observed for WT sample.  
Mutagenesis, protein purification, and crystallization 
HIV-1 protease variants were expressed from a Pet11A E. coli plasmid vector, as 
described (Prabu-Jeyabalan et al., 2004a). Native cysteines at positions 67 and 95 were 
both mutated to alanine. The variants for this study were generated using QuickChange 
site-directed mutagenesis kit (Stratagene, La Jolla, CA) to introduce the G16C, L38C, 
R14C, E65C, G16A and L38A substitutions. HIV-1 protease variants were expressed in 6 
liter cultures of E. coli BL21(DE3) cells at 37˚C. Protein expression was initiated at an 
OD600 of 0.6 by adding 2mM IPTG.  Cells were harvested after 3 hr and lysed using a 
cell disruptor. The inclusion bodies were isolated and resuspended in 7.5 M guanidinium. 
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The soluble fraction was isolated after centrifugation and the supernate was purified 
using superdex75 gravity gel filtration chromatography in 10 mM Tris pH 7.5 and 7M 
guanidine HCl at room temperature. The purified protease was then refolded by rapid 10-
fold dilution into the refolding buffer, containing 0.05 M sodium acetate (pH 5.5), 5% 
ethylene glycol, 10% glycerol, and 5 mM DTT (for the non-cross-linked protease) and in 
100mM sodium phosphate buffer (pH 7-7.5) (for the disulfide-bonded protease), both 
methods performed over ice. The refolded and diluted sample was concentrated and 
dialyzed against respective buffers to remove residual guanidine. Protease intended for 
crystallization was purified on a Pharmacia Superdex 75 FPLC column equilibrated with 
refolding buffer. Crystals were grown by the hanging drop vapor diffusion method at 
room temperature. The protein concentrations were 1.5–2 mg/ml. The inhibitor was 
crystallized in 5–10 molar excess. Inhibitor stock was made in dimethyl sulfoxide 
(DMSO). Small crystals started appearing after 6–9 days and grew at room temperature. 
Collection and processing of crystallographic data 
Protein crystals were harvested and flash frozen by dipping in liquid nitrogen. All data 
was collected under cryo conditions from various sources, including an in-house Rigaku 
X-ray generator with an R-axis IV image plate, and a synchrotron radiation source at 
Argonne National Laboratory (APS, Chicago, IL) BioCARS 14-BMC. Diffraction 
images were indexed and scaled using HKL2000 (Otwinowski and Minor, 1997b).  
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Crystallographic refinement and structural analysis 
Crystal structures were solved and refined using programs within the CCP4I suite(1994). 
Structures were solved by molecular replacement using PHASER (McCoy et al., 2007). 
Molecular replacement phases were improved by building solvent molecules using 
ARP/warp. Structures were refined with REFMAC 5 in the CCP4 suite using a 
combination of restrained and TLS (Painter and Merritt, 2006) (translation, libration, 
screw rotation) refinement. The possibility of over refinement was limited by using a free 
R value with 5% of the data. Electron density was viewed and interactive models were 
built using the program COOT(Emsley and Cowtan, 2004). Graphical visualization and 
analysis was carried out using PyMOL (Delano Scientific LLC). All figures were also 
generated in PyMOL. The disulfide bonds were analyzed using Disulfide Bond Analysis 
software (Wong and Hogg). Double difference plots were generated for 0 ns and 20 ns 
simulated structures of G16C/L38C in (oo) and (rr) to graphically visualize structural 
differences between them. Double difference plot analysis compares backbone shifts in 
closely related structures without adding bias towards methods used for superposition. 
Briefly, distances between all Cα atoms within the dimer were calculated for each 
structure. A distance-difference matrix was then computed for each atom for a given pair 
of complexes. The distance-difference matrix was then plotted as a contour plot using 
MATLAB (MathWorks, Natick, Massachusetts). Electron density analysis revealed that 
cysteine substitutions were well tolerated at all the positions (G16, L38, R14 and E65). 
However, disordered electron density was observed in the loops containing G16A and 
L38A substitutions in the DRV complex of alanine variant (G16A/L38A). Residues 36 
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and 37 were therefore, not modeled in one of the monomers of DRV(G16A/L38A) 
structure. Additionally, while the cross-linked (R14C/E65C)oo protease did not 
crystallize, the formation of cross-links was verified by Ellman’s test and mass 
spectrometry analysis as mentioned above. 
Enzyme kinetics 
Kinetics of each protease variant was assayed by its ability to hydrolyze the fluorogenic 
substrate HiLyte Fluor 488-Lys-Ala-Arg-Val-Leu_Ala-Glu-Ala-Met-Ser-Lys (QXL-520) 
(Anaspec, Inc., Fremont, CA) corresponding to the HIV-1 CA-p2 substrate. The assay 
was conducted in 96-well plates with 50 to 100nM protease in a total volume of 100 µl; 
the enzymatic reaction was initiated by adding 0-50µM substrate. Hydrolysis was 
monitored at 535 nm, while exciting at 485 nm using a Victor microplate reader 
(PerkinElmer, Waltham, MA).  The reaction buffer comprised 0.1 M sodium acetate, 1 M 
NaCl, 1 mg/ml BSA, 2% DMSO with and without 5 mM TCEP at a pH of 5.5. Relative 
fluorescence units were measured every 7 seconds and converted to concentration using 
standard calibration curves generated for HiLyte Fluor 488 at each substrate 
concentration. The Km values could not be obtained because of the limited solubility of 
fluorogenic peptide in reaction conditions. 
Molecular dynamics simulations 
MD simulations were performed using the program Sander in the AMBER 8 (Case et al., 
2005) (Assisted Model Building with Energy Refinement) package. Initial coordinates 
for the MD simulation of the “oo” protease were provided by the crystal structure 
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DRV(G16C/L38C)or with the ligand removed and an in-silico disulfide established 
between the cysteines in the second monomer. The initial coordinates for the MD 
simulation of the “rr” protease were provided by the crystal structure DRV(G16C/L38C)rr 
with the ligand removed. Three independent simulations each were carried out on 
G16C/L38C in both the cross-linked (oo) and non-cross-linked (rr) states. Each structure 
was solvated with the TIP3P water cubic box to allow at least 8 Å of solvent on each face 
of the protease. The dimensions of the final periodic box are 63 by 55 by 78 Å. A three-
step energy minimization process with the steepest descent method was used to allow the 
system to reach an energetically favorable conformation. In the first energy minimization 
step, all the heavy atoms of the protease were restrained with a harmonic force constant 
of 10 kcal mol-1Å-2. In the second step, only the backbone nitrogen, oxygen, and carbon 
atoms were restrained. In the third step, all atoms were allowed to move. Each of the 
three steps had 2000 cycles. The temperature of the energy-minimized system was then 
gradually raised from 50ºK to 300ºK in the NVT ensemble. Initial velocities were 
assigned according to the Maxwellian distribution with a random seed. In the 
thermalization process, heavy atoms were restrained with a harmonic force constant of 10 
kcal mol-1 Å-2. The whole process was 50 picoseconds (50,000 steps, each 1 fs). A 50-ps 
equilibration was then performed in the NPT ensemble without restraining heavy atoms. 
In the subsequent sampling MD simulations, each step was 2 fs, and the trajectory was 
recorded every 100 fs. The total simulation time was 20 ns. For the thermalization, 
equilibration, and sampling simulations, the SHAKE algorithm was applied to constrain 
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all hydrogen atoms. At every 1 ps, a snapshot was taken to be analyzed for the production 
phase. 
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Figure II.6.  Confirmation of cysteine cross-linking in (G16C/L38C)oo protease by 
mass spectrometry. (G16C/L38C)oo protein sample was treated with NEM, DTT and 
NMM in successive steps and spectra analyzed. The process was also repeated in the 
reverse order. No alkylation with the first alkylating reagent and complete alkylation with 
the second alkylating reagent were observed. Minor N-terminal alkylation was also 
observed  
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Fig. II.6 
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CHAPTER III 
STRUCTURAL, KINETIC, AND THERMODYNAMIC STUDIES ON 
SPECIFICITY DESIGNED HIV-1 PROTEASE 
 
 
 
 
 
 
 
 
 
 
93
  
AUTHOR CONTRIBUTIONS 
The work presented in the following chapter is a collaborative manuscript in preparation 
wherein Oscar Alvizo and I share the co-first authorship. Oscar Alvizo1 and Stepehen L. 
Mayo1,3 performed the positive design calculations and the kinetic assays. I performed 
the Isothermal titration calorimetry experiments and structural studies. Celia Schiffer, 
Oscar Alvizo and I wrote the chapter. 
 
 
 
 
 
 
 
 
1Biochemistry and Molecular Biophysics Option, California Institute of Technology, 
Pasadena, California 91125  
3Divisions of Biology, and Chemistry and Chemical Engineering, California Institute of 
Technology, Pasadena, California 91125  
 
94
  
ABSTRACT 
HIV-1 protease recognizes and cleaves more than 12 different substrates. While these 
substrates share no conserved motif, they are specifically selected for and cleaved by 
protease during viral maturation. Additionally, the drug resistant mutations of the viral 
protease that compromise inhibitor binding allow the continued recognition of all these 
substrates during viral replication. Since substrates and inhibitors compete for the same 
binding site, protease’s wide substrate specificity and the preferential selection of 
substrates over inhibitors in resistant variants are poorly understood. A better 
understanding of the determinants of substrate specificity may provide insights into the 
mechanism of altered molecular recognition in resistant proteases. Therefore, we 
engineered a specificity designed HIV protease using positive computational design, and 
validated the design using X-ray crystallography and enzyme biochemistry. The 
engineered variant, Pr3 (A28S/D30F/G48R), was designed to preferentially bind to one 
of HIV protease’s natural substrates; RT-RH over two others, p2-NC and CA-p2. In 
kinetic assays, RT-RH binding specificity for Pr3 increased three-fold compared to the 
wild-type (WT). These results were further confirmed by isothermal titration calorimetry. 
Crystal structures of WT protease and the designed variant in complex with RT-RH and 
CA-p2 and p2-NC, elucidated an altered flap conformation. Our results demonstrate that 
while substrate specificity could be engineered in HIV protease, the structural pliability 
of protease restricted the propagation of the predicted interactions. Thus, based on these 
data we propose that using positive computational design strategy to fully elucidate the 
determinants of substrate binding specificity in HIV-1 protease requires incorporation of 
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protein backbone flexibility during the design procedure.  
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INTRODUCTION 
Human immunodeficiency virus type-1 (HIV-1) protease recognizes and cleaves many 
natural substrates composed of diverse peptide sequences (Krausslich et al., 1989; Turner 
and Summers, 1999). Although studies have investigated the substrate binding and 
cleavage properties of proteases (Mahalingam et al., 2001; Moody et al., 1995; Pettit et 
al., 2005; Tie et al., 2005; Weber et al., 1997), the factors that determine the specificity of 
substrate binding still remain largely uncharacterized. Structural studies of HIV-1 
protease in complex with substrates and inhibitors indicate that the drug-resistant mutants 
of this enzyme have altered molecular recognition abilities; they still recognize the 
enzyme’s substrates but binding to inhibitors is disrupted (Croteau et al., 1997; Martinez-
Picado et al., 1999; Prabu-Jeyabalan, Nalivaika, and Schiffer, 2000; Prabu-Jeyabalan et 
al., 2003). The mechanisms involved in substrate recognition and binding of these drug-
resistant mutants have yet to be fully elucidated. To gain insight into these processes, an 
improved understanding of which residues dictate substrate binding specificity and how 
these sites evolve with the emergence of drug resistance is required.  
The “substrate envelope” concept states that the substrate specificity for HIV-1 protease 
is based on a conserved shape and not on the amino acid sequence of the substrate. This 
concept has been successfully used in designing robust protease inhibitors and in 
predicting the sites of drug-resistant mutations (King et al., 2004a; Prabu-Jeyabalan et al., 
2003; Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002). Additionally, several recent 
studies examined substrates from patient samples and found that the sequences of the 
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substrates co-evolved with major drug-resistant mutations in the protease (Kolli, Lastere, 
and Schiffer, 2006; Kolli et al., 2009; Prabu-Jeyabalan et al., 2004c). These findings 
suggest that for resistant protease variants, there is an alteration of substrate specificity 
that is selected for in the co-evolving substrate sites.  
Although extensive mutational studies have been done on HIV-1 protease, determining 
the basis of substrate specificity has proved challenging due to the enzyme’s plasticity. 
Mutational analyses of HIV protease and other proteases, such as those associated with 
Rous sarcoma virus or avian myeloblastosis virus (Cameron et al., 1994; Grinde et al., 
1992a; Grinde et al., 1992b; Konvalinka et al., 1992), have shown that substitutions in 
some sites can affect both the binding and catalytic efficiency of the enzyme. For 
example, replacing glycine with glutamic acid at position 48 in the flap region affects the 
specificity of HIV-1 protease (Loeb et al., 1989; Moody et al., 1995). The substituted 
glutamate side chain in the mutant enzyme interacts with a specific residue in the 
substrate and reduces the rate of cleavage; however, mutating the corresponding residue 
in the substrate largely restores activity (Moody et al., 1995).  
To fully understand how substrate peptides interact with the protease during binding and 
catalysis, several structural (Mahalingam et al., 2001; Prabu-Jeyabalan, Nalivaika, and 
Schiffer, 2000; Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002; Tie et al., 2005; Weber et 
al., 1997), kinetic (Gulnik et al., 1995; Ohtaka, Schon, and Freire, 2003; Pettit et al., 
2005; Tozser et al., 1991), and isothermal titration calorimetric studies were conducted 
on both active and inactive protease variants in complex with different substrate peptides 
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(Bardi, Luque, and Freire, 1997; King et al., 2004b; Luque et al., 1998; Velazquez-
Campoy et al., 2003). These studies have provided insight into the role of primary and 
compensatory mutations in resistant proteases and their substrates. However, a thorough 
understanding of substrate recognition would require the ability to predict and modulate 
substrate specificity.  Computational protein design can be used as a technique to probe 
what determines specificity.   
To investigate the determinants of substrate binding specificity in HIV-1 protease, we 
redesigned the enzyme to preferentially bind to one substrate, RT-RH, over two other 
substrates, p2-NC and CA-p2. HIV-1 protease is a unique enzyme because its 
symmetrical binding region recognizes and cleaves asymmetrical substrates. Although 
highly specific, this protease recognizes and hydrolyzes sequences that exhibit little 
sequence homology (Table III.I). Studies on substrate binding have shown that specificity 
is driven by steric complementarity of the peptide side chains.  Hydrogen bonds between 
enzyme and substrate side chains are rarely formed, and those that do form are not 
conserved between substrates. All the conserved hydrogen bonds occur between the 
enzyme and the substrate backbone, forming an extensive network that locks the 
substrate backbone into the proper conformation for peptide hydrolysis (Prabu-Jeyabalan, 
Nalivaika, and Schiffer, 2002).  However, for most enzymes hydrogen bonds are 
considered crucial for substrate specificity. HIV protease’s broad substrate specificity 
could be due to the lack of specific hydrogen bonds to peptide side chains (Prabu-
Jeyabalan, Nalivaika, and Schiffer, 2002). If this hypothesis is correct, then variants that 
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can form specific hydrogen bonds to wild-type (WT) substrates should exhibit an 
increase in specificity (Wells et al., 1987).  
The question of specificity has been addressed in the computational design of other 
proteins. While electrostatic interactions are important in discriminating between side 
chains with opposite charges, and van der Waals forces can be used to select for side 
chains with specific geometries, optimizing for hydrogen bonding can be considered a 
purely positive design approach. Positive design is when a particular property is being 
selected for, rather than designing against a particular property, which would be 
considered negative design.  Positive design proved to be a successful approach in the 
computational design of calmodulin (CaM) specificity (Shifman and Mayo, 2002; 
Shifman and Mayo, 2003). Designs used the substrate-bound compact structure of CaM 
to produce mutants with increased specificity towards a target peptide (Green et al., 2006; 
Shifman and Mayo, 2002). A similar approach was also effectively applied to the re-
engineering of PDZ domains to bind novel sequence targets (Reina et al., 2002).  
In addition to designing variants with increased specificity towards peptides, 
computational protein design has been used to engineer proteins with improved protein-
protein specificities. Focusing on positive design resulted in more stable complexes, 
whereas including negative design provided specificity at the cost of stability (Bolon et 
al., 2005). Another example is the redesign of a protein complex between colicin E7 
DNAse and Im7 immunity protein, where a new hydrogen bond network was predicted at 
the interface that provided increased specificity for the cognate dimer over the non-
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cognate dimer (Joachimiak et al., 2006). The success of the redesign was attributed to 
using positive design on an ensemble and designing against the native complex.  
Previous attempts to engineer protease specificity have largely focused on the rational 
design of trypsin (Hung and Hedstrom, 1998; Kurth et al., 1998; Kurth et al., 1997; Page 
et al., 2003). Trypsin is a hydrolase that is highly specific for Lys- and Arg-containing 
peptides, whereas chymotrypsin favors peptides with aromatic residues such as Phe, Tyr, 
and Trp. A trypsin mutant was successfully engineered with specificity similar to that of 
chymotrypsin (Hedstrom, Szilagyi, and Rutter, 1992). Since both enzymes have similar 
tertiary structures, replacing trypsin residues around the catalytic binding pocket and 
surface loops with those of chymotrypsin resulted in a preference for hydrophobic amino 
acids. The work presented here uses positive design to increase the specificity of HIV-1 
protease. 
Our redesign of HIV-1 protease considers the entire binding region, which is composed 
of eight binding pockets. In this work, the computational approach was aimed at re-
engineering the binding pockets to increase specificity for one of HIV-1 protease's 
natural substrates, RT-RH. Unlike CaM or PDZ domains, HIV protease is catalytic. 
Hence, the designs were intended to preserve the proteolytic activity in addition to 
increasing specificity for RT-RH, thereby, bridging the gap between the computational 
design of specificity and catalytic activity (Wilson, Mace, and Agard, 1991). One 
protease variant, Pr3 (A28S, D30F, G48R), was designed to bind RT-RH with increased 
specificity, and was tested experimentally using a combination of structural 
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(crystallography), functional (kinetic), and thermodynamic (isothermal titration 
calorimetric (ITC)) assays. While WT HIV-1 protease is a symmetric dimer, the three 
mutations predicted by the positive design were in the same monomer generating an 
asymmetric dimer. Therefore, the predicted substrate specificity was based on the 
asymmetry of the designed protease. The kinetic assays revealed that the designed Pr3 
variant (Fig. III.1) indeed exhibits specificity towards RT-RH that is increased three- and 
four-fold compared to the p2-NC and CA-p2 substrates, respectively (Table III.2). ITC 
studies indicated that RT-RH binding is consistent with the kinetic data for RT-RH 
(Table III.3). Crystal structures were obtained for the WT and specificity designed variant 
Pr3 in complex with RT-RH and p2-NC, respectively. The structural analysis, however, 
revealed that the intended asymmetry was rendered ineffective due to the plasticity of the 
enzyme, and the interactions predicted by positive design were only partially formed. 
Overall, the experimental data provides valuable insights into the positive computational 
design approach as an invaluable tool in facilitating our understanding of the factors that 
govern substrate binding specificity for functionally complex proteins such as HIV-1 
protease. This study also demonstrates the challenges posed by protein plasticity in the 
accurate prediction of protein behavior. The field of computational protein design is ever 
evolving, and this study proposes some additional parameters that might be considered in 
making the process more robust and dependable.  
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Table III.1.  Sequences of peptide substrates hydrolyzed by wild-type HIV-1 
protease 
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Table III.1 
 Residue position 
Substrate P4 P3 P2 P1 P1′  P2′  P3′  P4′  
MA-CA Ser Gln Asn Tyr Pro Ile Val Gln 
CA-p2 Ala Arg Val Leu Ala Glu Ala Met 
p2-NC Ala Thr Ile Met Met Gln Arg Gln 
NC-p6 Pro Gln Asn Phe Leu Gln Ser Arg 
IN p6 Lys Glu Leu Tyr Pro Leu Thr Ser 
TF-PR Ser Phe Asn Phe Pro Gln Ile Thr 
PR-RT Thr Leu Asn Phe Pro Ile Ser Pro 
RT-RH Ala Glu Thr Phe Tyr Val Asp Gly 
RT-IN Arg Lys Ile Leu Phe Leu Asp Gly 
P1–P1′ is the scissile bond. 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Figure III.1.  The predicted sites of mutations in the specificity designed Pr3 HIV-1 
proteases. In this single-chain HIV protease structure, the sequences corresponding to 
the two monomers are colored differently: monomer A is in magenta and monomer B is 
in cyan. The substrate is shown in green with respect to the scissile bond; N terminal 
residues colored green and C terminal residues colored limon green. 
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Fig. III.1 
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RESULTS AND DISCUSSION 
Protease design calculations and prediction of mutants 
HIV Protease was chosen as an ideal target to alter specificity, as it naturally recognizes 
diverse substrates that should be distinguishable based on their sequences and crystal 
structures are available for many of these substrates (Prabu-Jeyabalan, Nalivaika, and 
Schiffer, 2002). Three crystal structures of HIV protease, each bound to a different native 
substrate, were used in the design of variants (PDB ID: 1F7A, 1KJG, and 1KJ7) (Prabu-
Jeyabalan, Nalivaika, and Schiffer, 2002). The entire binding region of HIV protease 
comprising eight binding pockets was included in the design. Due to the large size of the 
binding region, only side chains directly contacting the substrate were considered. 
Previous studies have demonstrated that engineered single chain dimers (Bhat et al., 
1994; Bhat et al., 1995) of HIV protease preserve wildtype specificity and are better 
suited for engineering in specificity.  To conserve function, the catalytic aspartates at 
positions 25 and 125 were kept in their crystallographic conformations. Early design 
calculations indicated that the RT-RH-bound structure (1KJG) was the most promising 
template, and was selected for optimization. 
The design was initially divided into eight small calculations, one for each binding 
pocket. Given that HIV protease, a symmetrical dimer, binds to asymmetrical peptides, 
the two-fold symmetry of the binding region was not conserved. For each pocket, 
residues within 4.2 Å of a substrate side chain were defined as being in the first shell, and 
residues within 4.2 Å of any first shell residue were defined as being in the second shell. 
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First shell residues were allowed to mutate, whereas second shell residues and the 
substrate's side chains were allowed to change conformation but not amino acid identity. 
Optimization of interactions within the binding region was expected to increase 
specificity (Park et al., 2005). The individual pocket designs (Fig. III.2) were carried out 
in the following sequential order: 
S1S1′S2S2′S3S3′S4S4′ 
Mutations predicted from preceding calculations were carried over to the next design. As 
a result, the final design on the S4′ binding pocket contained all the mutations from 
preceding designs.  One of the major drawbacks with designing individual pockets is 
their discrete nature. To mitigate this problem, positions that predicted reasonable 
mutations in the individual pocket calculations were simultaneously designed in the 
context of the entire binding region.  
Based on the results from discrete pocket predictions, four positions (30, 48, 82, and 130) 
were selected for simultaneous design in the 1KJG crystal structure. All the other 
positions that had been considered in individual binding pocket calculations were floated. 
This simultaneous design predicted specificity-optimized mutations at all four of the 
selected positions. Position 30 was mutated to Phe due to improved van der Waals 
interactions with AlaP4, and position 48 replaced Gly with Arg to form a salt bridge with 
GluP3. The mutations predicted at positions 82 (VI) and 130 (DN) were fairly 
conservative, and were expected to have little impact on specificity for the target 
substrate, RT-RH. To test the robustness of the calculation, solvation model was changed 
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from a solvent exclusion-based one to a surface area-based one and the individual pocket 
designs were repeated (Lazaridis and Karplus, 1999). This resulted in an additional 
change from Ala to Ser mutation at position 28; Ser predicted to form a hydrogen bond 
with the p2 Thr of the substrate (Fig. III.3). After considering the mutations from all the 
preceding designs, a four-point mutant (A28S/D30F/G48R/V82I) was selected for further 
evaluation.  
This combination of mutations was evaluated for specificity towards the RT-RH 
sequence compared with the other substrate sequences. Side-chain placement calculations 
were carried out on the four-point mutant and on the WT protease using three substrate-
bound crystal structures (1KJG, 1F7A, and 1KJ7) in which the protease is bound to RT-
RH, CA-p2, or p2-NC peptide, respectively. Energy analysis of the side-chain placement 
results indicated that the four-point mutant would stabilize the RT-RH substrate by 7.8 
kcal/mol relative to the WT sequence. In contrast, a much smaller increase in stability 
(1.96 kcal/mol) was predicted for the p2-NC peptide, and a decrease in stability was 
predicted for the CA-p2 peptide. The majority of increase in stability for RT-RH is 
expected to be due to a new hydrogen bond and salt bridge that are predicted to form as a 
result of the A28S and G48R mutations.  The G48R mutation appears to stabilize 
interactions with RT-RH while disfavoring binding of CA-p2 and p2-NC. Arg at position 
48 is able to form a salt bridge with Glu at the P3 position on RT-RH (Fig. III.3). The 
absence of Glu at P3 in the other two substrates prevents a similar interaction (Table 
III.1). Position P3 in p2-NC is a Thr, which is too small to accommodate even a hydrogen 
bond. CA-p2 contains an Arg at P3, which would form a repulsive interaction between 
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the two Arg’s, but due to the two-fold symmetry in the binding site of HIV protease, the 
CA-p2 substrate is likely to bind in the opposite orientation where P3Arg can interact 
with Ala148 instead.  Similarly, for p2-NC; although there are no unfavorable 
interactions predicted between Arg48 and P3Thr, binding in the alternate conformation 
would result in Arg48 having direct contact with P3′Arg (Table III.I). As a result, the 
mutation to an Arg at position 48 contains negative design features as well as positive 
design attributes.  The V82I and D130N mutations were predicted to be beneficial in 
binding all the three substrates considered, and thus were dropped from experimental 
validation as not altering the specificity for the RT-RH target sequence.  Thus the final 
single chain construct designed for experimental validation was Pr3 (A28S/D30F/G48R) 
with the second monomer maintaining a wildtype sequence.   
Experimental determination of binding and kinetic parameters for specificity 
designed protease variants 
To assess the accuracy of the computational predictions, the designed protease variant 
Pr3 and WT protease were tested for their catalytic efficiency for three substrates: RT-
RH, CA-p2, and p2-NC. Since the designs allowed asymmetrical mutations, in 
constructing the WT and mutant proteins, a tethered dimer was used to ensure a 
heterodimer complex. Therefore, all experimental data was collected using single chain 
HIV-1 protease in which the two monomers were tethered with a five amino acid flexible 
linker (GGSSG) (Bhat et al., 1994; Bhat et al., 1995; Cheng et al., 1990; Das, Rao, and 
Hosur, 2007). Kinetic experiments for the WT and Pr3 protease were carried out and 
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resulting kinetic parameters for substrate cleavage were compared. Due to minimal 
peptide solubility, limited data was obtained for substrates with Kms greater than 50 µM. 
Nevertheless, Vmax/Km values were successfully obtained using hydrolysis rates at low 
substrate concentrations. A significantly different specificity profile was observed for Pr3 
compared to WT protease (Table III.2). Although the Vmax/Km(s−1) for RT-RH was 
relatively unaffected, the values for p2-NC and CA-p2 decreased significantly. The 
normalized values show that, relative to WT, specificity towards the RT-RH substrate 
increased two-fold and nine-fold over the p2-NC and CA-p2 substrates, respectively. The 
experimental kinetic results indicated that positive design resulted in a mutant with 
effectively increased substrate specificity.   
To complement the results on enzyme kinetics, isothermal titration calorimetry (ITC) was 
performed to measure the binding parameters for the inactive (D25N) variant of the 
designed protease Pr3 to assess the thermodynamics of peptide recognition. Data could 
only be collected for RT-RH, possibly due to the extremely weak binding affinities of the 
other two substrates (p2-NC and CA-p2). For RT-RH, single chain WT protease 
exhibited a dissociation constant (Kd) of 4.4 µM while binding 1.75 fold more tightly to 
Pr3 (Table III.3). Hence, the designed protease Pr3 binds the target substrate with higher 
affinity compared to the WT protease. 
 
111
  
Crystal structures of the specificity designed HIV protease-substrate complexes 
After using computational protein design to alter the specificity of HIV-1 protease and 
acquiring experimental data to support the design predictions, one major question 
remained:  Are the interactions predicted by the protein design methodology an accurate 
representation of the actual mode of substrate binding to these specificity-designed 
proteases? To address this question, the crystal structures of catalytically inactive variants 
of Pr3 and single-chain WT protease were determined in complex with the three 
substrates: RT-RH, CA-p2, and p2-NC, respectively (with the exception of Pr3 in 
complex with CA-p2, which did not crystallize). The crystallographic and refinement 
statistics are listed in (Table III.4). 
The overall three-dimensional structure of the tethered single-chain WT protease in 
complex with RT-RH was similar to the dimeric WT protease-substrate structure 
determined previously (Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002). In the substrate-
bound crystal structures of Pr3, however, the 2Fo-Fc and Fo-Fc maps showed ambiguous 
densities at the sites of engineered substitutions. The side-chain density for the A28S 
substitution was partially present on both sides; hence, A128 also showed partial 
occupancy of serine. These ambiguities in the electron density maps suggested that the 
protease-substrate complex was not uniquely oriented in the crystal lattice. The observed 
electron density is a composite of four differently oriented forms of the same complex, 
which is averaged over the crystal lattice. The complete side-chain density for D30F 
could not be traced in any of the structures. Despite the structures being averages, R48 
112
  
was seen predominantly only on one side of the dimeric protease and was used to 
distinguish the two monomers in these tethered dimer structures. All the structural 
analyses and alignments are thus defined based on this orientation.  
 
Comparison of predicted and experimental structures 
Structural analysis revealed a partially ajar flap conformation for one of the flaps in each 
of the complexes, as we previously observed (Prabu-Jeyabalan et al., 2006). The designed 
mutations possibly allowed several low energy flap conformations to be accessed. 
Curiously, no trend was seen in the identity of the partially open flap; in some structures, 
one monomer (monomer A) with the G48R discernable had the flap ajar, whereas in 
others, the flap was ajar in the other monomer (monomer B). Analysis of crystal packing 
showed that there is enough space within the crystal lattice to allow either conformation 
of the flap to be present.  
The orientations of the substrates are also complicated in the complexes. The 
sequence of RT-RH is highly symmetric in shape about the scissile bond (Table III.1) and 
binds in both the WT and Pr3 variant complexes in two orientations.  The sequence of 
p2-NC is asymmetric (Table III.1) and is uniquely oriented in the complex, although the 
single-chain dimer is averaged (Fig. III.4). Interestingly, in all the complexes with CA-p2 
and p2-NC, the flap on the P′ side of the substrate was ajar, with the closed conformation 
over the P side (Fig. III.4). This suggests that the flap interacting with P3-P1 residues of 
the substrate may engage first, possibly more tightly, and that these designed proteases 
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have stabilized a structural intermediate of substrate recognition (Prabu-Jeyabalan et al., 
2006). 
Since the G48R mutation in Pr3 introduced an aspect of negative design in substrate 
binding for the sequences of CA-p2 and p2-NC, these substrates were predicted to bind in 
only one of the two possible orientations with respect to the designed proteases. 
However, in the p2-NC complex with Pr3, both possible orientations of substrate binding 
were observed. In the Pr3 crystal structures, R48 was in a different conformation than 
what was predicted by design (Fig. III.3, Fig. III.4 and Fig. III.5a). The observed 
conformation of R48 in these complexes eliminated any possibility of electrostatic 
clashes with Arg in p2-NC and possibly in CA-p2, thereby allowing substrate binding in 
both possible orientations. The interaction predicted for A28S and D30F substitutions 
also only partially agreed with the observed interactions in the crystal structures (Fig. 
III.5b and c). These results indicate that the plasticity of HIV-1 protease is critical to 
understanding the protease-substrate relationship.  
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Table III.2.  Experimental kinetic values for WT HIV-1 protease and specificity 
designed Pr3 Variant for the cleavage of three peptide substrates. 
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Table III.2 
 RT-RH p2-NC CA-p2 
Protease Vmax/Km 
(s−1) 
Normalized Vmax/Km 
(s−1) 
Normalized Vmax/Km 
(s−1) 
Normalized 
WT 1.65E−03 1.00 3.70E−04 0.22 1.34E−03 0.81 
Pr3 1.13E−03 1.00 1.00E−04 0.09 1.00E−04 0.09  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Table III.3.  Thermodynamic parameters for binding of RT-RH to single-chain WT 
HIV-1 protease and the specificity designed inactive variant Pr3 
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Table III.3 
Protease Kd (μM) ∆H (kcal/mol) −T∆S (kcal/mol) ∆G (kcal/mol) 
Single-chain  
WT 4.43 ± 0.9 0.198 ± 0.06 −7.25 −7.05 ± 0.122 
Pr3 2.52 ± 0.4 2.49± 0.2 −9.86 −7.37 ± 0.089 
Errors on thermodynamic parameters are derived from the fitting error after repeating the 
experiments at least three times. 
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Figure III.2.  Schematic representation of the binding pockets of substrate-protease 
complex. The substrate interaction sites are designated as S4-S4’ pockets and the 
equivalent sites for protease are referred to as P4-P4’ sites. The substrate is represented in 
green, protease monomer A is in magenta and monomer B is in cyan. The scissile bond is 
between P1 and P1’ residues. 
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Fig III.2 
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Figure III.3.  Predicted interactions of the designed mutations in Pr3 
(A28S/D30F/G48R) protease with the substrate RT-RH displayed in stereo. RT-RH 
is shown in green (residues N and C terminal with respect to the scissile bond are colored 
green and limon green, respectively) and the two monomers are colored magenta and 
cyan, respectively. G48R was predicted to form a salt bridge with Glu at the P3 position 
in RT-RH. Improved van der Waals interactions were predicted for D30F with Ala at P4 
in RT-RH and A28S was predicted to make a hydrogen bond with Thr at p2 in RT-RH.  
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Fig III.3 
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Table III.4. Crystallographic statistics for RT-RH, CA-p2, and p2-NC substrate 
complexes with single-chain WT and Pr3 proteases 
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Table III.4 
Variable PrWT-RTRHb PrWT-p2NCa PrWT-CAp2a Pr3-RTRHb Pr3-p2NCa 
Resolution (Å) 1.9 1.66 1.9 1.9 1.7 
Temperature (K) 100 100 100 100 100 
Space group p212121 p212121 p212121 p212121 p21 
Unit cell parameters      
a (Å) 51.2 51.0 51.2 51.1 51.06 
b (Å) 58.7 58.8 58.7 59.4 59.06 
c (Å) 61.8 61.8 61.8 62.2 61.8 
Z 4 4 4 4  
Rmerge  (%) 6.6 4.9 5.4 6.8 4.5 
Completeness (%) 91.8 95.4 99.2 99.4 99.9 
Total reflections 93941 152868 120343 110382 168022 
Unique reflections 14007 21538 50132 33665 40661 
I/σ 10.4 14.5 12.6 14.7 12.8 
RMSD (Å)      
Bond length (Å) .011 .010 .007 .009 .009 
Bond angles 1.35 1.4 1.32 1.43 1.48 
Rfactor (%) 21.3 23.1 24.1 20.3 20.3 
Rfree (%) 25.2 26.2 27.3 26 24.7 
Redundancy (%) 6.7 7.1 4.4 3.3 4.1 
aData collected by Annie Heroux (mail-in-crystal program @ BNL). 
bData collected at 14-BMC, BioCARS @ Argonne Photon Source. 
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Figure III.4.  Pr3 in complex with p2-NC. The substrate is uniquely oriented in the 
structure. p2-NC is shown in green (residues N and C terminal with respect to the scissile 
bond are colored green and limon green, respectively) and the two protease monomers 
are colored magenta and cyan, respectively. The flap corresponding to the P side of the 
substrate (N terminal) is closed irrespective of the engineered mutations, suggesting that 
the flap interacting with the P3-P1 residues may engage first and more tightly than the 
one interacting with the P′ residues.  
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Figure III.4 
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Figure III.5.  Predicted vs. observed interactions for the RT-RH complexes of WT 
and Pr3 protease. For the predicted WT-RTRH complex, RT-RH is colored green and 
the two monomers are colored magenta and cyan, respectively. Pr3-RTRH complex is 
represented in the corresponding lighter colors. A) The orientation of the G48R side 
chain observed in the crystal structures differs from the predicted orientation. For Pr3-
RTRH complex, RT-RH is modeled in both orientations and P3 Glu side chain could not 
be modeled in the structure due to incomplete density. B) D30F was predicted to make 
improved van der Waals interactions with Ala at P4 in RT-RH. While the P4 Ala side 
chain could not be modeled in the Pr3-RTRH structures due to incomplete density, the 
interaction distance could support the predicted improvement in van der Waals 
interactions. C) A28S was predicted to make a hydrogen bond with Thr at P2 in RT-RH. 
Ambiguous side chain density for the P2-Thr side chain was observed in the Pr3-RTRH 
crystal structure, however, for one possible P2-Thr conformation, the predicted hydrogen 
bond could likely form.  
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Fig III.5 
 
 
 
 
 
A
B
C
48R 48R
30F 30F
28S 28S
128
  
CONCLUSIONS 
A logical computational design approach was applied to determine the factors governing 
the substrate binding specificity of HIV-1 protease. Positive design was used to redesign 
the protease to preferentially bind to one of its natural substrates, RT-RH, relative to two 
other substrates, p2-NC and CA-p2. Based on this design strategy, one of the predicted 
protease variants was tested experimentally, and kinetic, binding, and structural data were 
obtained.  While the binding and kinetic data agreed well with the design, the predictions 
were only partially realized in the crystal structures. The crystallographic analysis was 
complicated by the flexibility of the flaps and the averaged orientation of the molecules 
in the crystal lattice, which generated complex averaged density maps. The internal two-
fold symmetry in the primary sequence of RT-RH further complicated the structural 
analysis of RT-RH complexes and hence the analysis of predicted vs. observed 
interactions. The charged substitution, G48R exhibited an unpredicted effect on the 
specificity of protease-substrate interactions, likely due to decreased backbone flexibility 
but increased conformational flexibility of extended charged side chain.  Additionally, 
while the homodimeric HIV protease accommodated the design of asymmetry, the 
positive design method was ineffective in predicting the observed substrate binding 
orientation. Thus, the crystal structures partly supported the design and revealed an 
unanticipated influence of inherent protease flexibility on protease structure.  
Predicting the true impact of introduced hydrogen bonds and van der Waals clashes is 
difficult in a computational protein design procedure that requires the use of a fixed 
129
  
backbone. Proteins are intrinsically dynamic and can adapt to mutations to prevent van 
der Waals violations. With the fixed backbone restriction, there is no means of modeling 
protein motions that might accommodate unfavorable van der Waals energies. In 
addition, the discrete nature of the rotamer library can exclude side-chain conformations 
that might prevent atomic clashes. Minimization and the use of multiple crystal structures 
may have assisted, however, quickly becomes computationally expensive, when 
performed at every step. A good alternative to minimization is the parallel design of 
multiple static backbone structures that represent a protein's dynamic range. Future 
studies in computational protein design will most likely incorporate methods that include 
protein backbone motion. 
In summary, the results support the hypothesis that flexibility in HIV-1 protease strongly 
influences substrate recognition and binding.  The results obtained from this study 
highlight the importance of incorporating extensive protein flexibility into the design 
process to enhance its predictive power.  Algorithms that include backbone flexibility and 
degrees of freedom, side chain dynamics, protein symmetry, and the internal symmetry of 
substrates and ligands would go a long way in improving the designs. 
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MATERIALS AND METHODS 
Computational positive design  
The crystal structure of HIV-1 protease bound to the RT-RH substrate (PDB code 1KJG) 
was used as the positive design scaffold.  The crystal structure was subjected to 50 steps 
of minimization to relax van der Waals interactions, atomic bonds, and angles.  Residues 
within 4.2 Å of a substrate side chain were selected for design (first shell residues); 
residues within 8.4 Å not selected to be in the first shell (second shell residues) and 
substrate side chains were floated (allowed to change conformation but not amino acid 
identity).  Five conserved water molecules, residues hydrogen bonding to the waters (8, 
29, 87, 108, 129, and 187) and catalytic residues (25 and 125) were fixed in their 
crystallographic conformations.  In addition, proline-containing positions (81 and 181) 
were only allowed to change conformation. 
A Dunbrack and Cohen-based backbone dependent rotamer library was used for side-
chain optimization.  χ1 and χ2 values were expanded one standard deviation for all amino 
acids.  In addition, the crystallographic rotamer at every design position was included.  
Either a solvent exclusion-based or an atomic surface area-based solvation potential was 
used.  A rotamer probability scale factor of 0.3 proportionally penalized side-chain 
conformations based on their pre-calculated probabilities.  All other parameters and 
potential functions used have been described previously (Dahiyat, Gordon, and Mayo, 
1997; Dahiyat and Mayo, 1997a; Dahiyat and Mayo, 1997b; Dahiyat, Sarisky, and Mayo, 
1997). An optimization algorithm based on the Dead-End Elimination (DEE) theorem 
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was used in the design of individual pockets (Gordon et al., 2003).  Designs on the entire 
binding region required the use of the FASTER algorithm to achieve convergence 
(Desmet, Spriet, and Lasters, 2002). A combination of energy analysis and visual 
inspection of the predicted low-energy conformations was used to identify promising 
mutations. 
Mutagenesis, protein purification, and crystallization 
As described previously (Hui et al., 1993; Prabu-Jeyabalan et al., 2004c), HIV protease 
variants were expressed from a pET11a Escherichia coli plasmid vector.  The gene 
construct coded for two copies of the HIV monomer linked by the nucleotide sequence 
that codes for Gly-Gly-Ser-Ser-Gly (Bhat et al., 1994; Cheng et al., 1990).  The 
nucleotide sequence that coded for each monomer was unique; the use of two different 
sequences allowed for site-directed mutagenesis to be targeted to a specific monomer.  
Cysteines at positions 67, 95, 167, and 195 were mutated to Leu, Met, Leu, and Met, 
respectively.  The QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) 
was used to introduce the D25N substitution in order to inactivate the designed variants 
for ITC studies. 
HIV protease variants were expressed in 2-liter cultures of E. coli BL21(pLysS) cells at 
37˚C.  Protein expression was initiated at an OD600 of 0.6 by adding IPTG.  Cells were 
harvested after 3 h and lysed using an emulsiflex.  The active and inactive variants of the 
designed proteases were purified and refolded by two different methods. For active 
variants, the inclusion bodies were isolated and resuspended in 66% acetic acid and 
132
  
diluted 10-fold in water.  The soluble fraction was isolated after centrifugation and 
dialyzed overnight against 100% water.  Any precipitate was removed and the resulting 
sample was purified using cation exchange chromatography.  The pure sample was 
desalted and lyophilized.  Active enzyme was produced by taking the lypholized sample 
in 8 M guanidinium and refolding the protein at 0.6 mg/mL in 55 mM Tris pH 8.2, 10.56 
mM NaCl, 0.44 mM KCl, 0.055% PEG 3350, 550 mM guanidine HCl, 1.1 mM EDTA, 
440 mM sucrose, and 1 mM DTT at 0˚C. For inactive variants, the inclusion bodies were 
isolated and resuspended in 50% acetic acid. The soluble fraction was isolated after 
centrifugation and the resulting sample was purified using Superdex75 gravity gel 
filtration chromatography in 50% acetic acid.  The purified inactive protease, in 50% 
acetic acid, was then refolded by rapid 10-fold dilution into the refolding buffer, 
containing 0.05 M sodium acetate (pH 5.5), 5% ethylene glycol, 10% glycerol, and 5 mM 
DTT, over ice. The refolded and diluted sample was concentrated and dialyzed to remove 
residual acetic acid. Protease intended for crystallization was further purified on a 
Pharmacia Superdex75 FPLC column equilibrated with refolding buffer. Crystals were 
grown by the hanging drop vapor diffusion method at room temperature. The protein 
concentrations used were approximately 1.5–2 mg/ml. The substrates were crystallized in 
5–10 molar excess. Substrate stocks were made in DMSO. Small crystals started 
appearing after about 6–9 days and grew over time at room temperature. 
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Protease kinetics 
Kinetics of protease activity were determined using three DABCYL/EDANS substrates: 
NH2-D(Edans)-KARVLAEAM-K(Dabcyl)-R-COOH, NH2-D(Edans)-ATIMMQRGN-
K(Dabcyl)-R-COOH, and NH2-D(Edans)-AETFYVDGA-K(Dabcyl)-R-COOH, which 
are derivatives of CA-p2, p2-NC, and RT-RH substrates, respectively (Matayoshi et al., 
1990). Hydrolysis was monitored at 490 nm while exciting at 340 nm in a PTI 
fluorimeter.  The reaction buffer was composed of 0.1 M sodium acetate, 0.1 M NaCL, 1 
mM EDTA, 1 mM DTT, 1 mg/ml BSA, and 10% DMSO at a pH of 4.7.   
Isothermal titration calorimetry 
A VP-ITC (MicroCal, Northampton, MA) isothermal titration calorimeter was used to 
determine the thermodynamic parameters of peptide binding to the designed proteases. 
The buffer used for all protease and peptide solutions consisted of 10 mM sodium acetate 
pH5.0, 2% DMSO, and 2 mM Tris (2-carboxyethyl) phospine (TCEP). A 750 µM 
solution of RT-RH was directly titrated into solutions containing 45-67 µM of the D25N 
(inactive) variants of WT protease and Pr3, respectively. The experiments were 
performed at 15°C and were repeated at 10°C and 25°C for the WT protease, as at 15°C 
the calculated enthalpy of binding was zero. Each experiment was repeated at least in 
triplicate and data were processed using the Origin 7 software package from MicroCal. 
 
134
  
Crystallographic data collection and processing 
Protein crystals were harvested and flash frozen by dipping in liquid nitrogen. All data 
was collected under cryo conditions from various sources, including an in-house Rigaku 
X-ray generator with an R-axis IV image plate, a synchrotron radiation source at Argonne 
National Laboratory (APS, Chicago, IL) BioCARS 14-BMC, and a synchrotron radiation 
source at Brookhaven National Laboratory (BNL, Upton, NY) X-25 through a mail-in 
crystal program. Diffraction images were indexed and scaled using HKL2000 
(Otwinowski and Minor, 1997a). Complete data collection statistics are listed in (Table 
III.4). 
Structure solution and crystallographic refinement 
Crystal structures were solved and refined using the programs within the CCP4I suite 
(1994). Structure solution was carried out by molecular replacement using PHASER 
(McCoy et al., 2007). Molecular replacement phases were further improved by building 
solvent molecules using ARP/warp (Langer et al., 2008; Morris, Perrakis, and Lamzin, 
2002). Refinement was carried out with REFMAC 5 (Murshudov, Vagin, and Dodson, 
1997; Potterton et al., 2004) in the CCP4 suite with cycles of restrained and TLS 
(translation, libration, screw rotation) refinement (Painter and Merritt, 2006). A free R 
value with 5% of the data was used to limit the possibility of over refinement. Electron 
density was viewed and interactive model building was carried out by using program 
COOT (Emsley and Cowtan, 2004). Refinement statistics are also shown in (Table III.4). 
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Analysis and comparison to experimental structures 
Graphical visualization and analysis was carried out using PyMOL (Delano Scientific 
LLC) (DeLano, 2002b). All figures were also generated in PyMOL. 
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ABSTRACT 
The 13 known substrate cleavage sites of HIV-1 protease share little sequence identity 
and lack an obvious consensus binding motif. The factors governing this substrate 
recognition and specificity are poorly understood. While it is difficult to predict with 
accuracy the local preference for a specific amino acid at a particular position in the 
cleavable substrate sequence, the N terminal region (residues P3-P1) of substrates is 
suggested to initiate recognition. In this study we investigated structurally, the relative 
preference of N or C terminal substrate region in determining binding affinity to protease. 
We determined 5 crystal structures of active protease in complex with decameric peptide 
sequences corresponding to MA-CA, RH-IN, CA-p2, p1-p6 and RT-RH cleavage sites, 
respectively. Structural analysis revealed that these decameric peptides were cleaved by 
the active protease within the crystallization drop and protease crystallized with N 
terminal product bound in the active site. The C terminal product was either missing or 
disordered, as judged by the quality of electron density maps in that region. Structural 
data demonstrates that protease exhibits binding preference for the N terminal product 
sequence compared to the C terminal sequence and supports the hypothesis that N 
terminal substrate has a higher preferential binding affinity to the protease compared to 
the C terminal substrate sequence.  
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INTRODUCTION 
HIV-1 protease has broad substrate specificity. There are 12 known viral substrate sites 
recognized and cleaved by protease (de Oliveira et al., 2003) (Table IV.1). Protease also 
targets the translation initiation factor in the infected host cells for cleavage (Perales, 
Carrasco, and Ventoso, 2003; Ventoso et al., 2001), thereby directly inhibiting protein 
translation. While several studies have explored the molecular basis of substrate binding 
specificity in HIV-1 protease (Griffiths et al., 1992; Pettit et al., 1991; Ridky et al., 1996; 
Tozser et al., 1997a; Tozser et al., 1991; Tozser et al., 1992), the factors responsible, 
however, are still poorly understood.  
HIV protease substrate specificity typically includes 7 sub-sites (S4-S3’) within the 
enzyme that are involved in direct interaction with the substrates/inhibitors. The 
equivalent residues in the substrates are referred to as P4-P3’ (Schechter and Berger, 
1967). While the shortest peptide substrates that can be cleaved by protease are 
approximately six amino acids in length, efficient cleavage requires seven or more 
residues, as the amino acid identities outside the cleavage site can also influence binding 
and cleavage (Griffiths et al., 1992; Tozser et al., 1991). As previously described, HIV 
protease cleaves a large viral polyprotein, Gag-Pro-Pol, to release several structural 
proteins and viral enzymes. The context of the cleavage sites in this large polyprotein is 
known to affect the rates of cleavage. HIV protease must cleave the polyprotein at not 
only distinct sites but also at distinct relative rates in order for the virus to mature to an 
infectious form (Kohl et al., 1988). There are also differences in the cleavage rates for 
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different sites when presented in a polyprotein vs. short peptide models of the natural 
substrates (Pettit et al., 1994; Tritch et al., 1991). For example, MA/CA cleavage site, 
…SQNYP*PIVQ…, is cleaved faster in a gag polyprotein than the CA/p2 cleavage site, 
…ARVL*AEAM…,  whereas CA/p2 sequence is cleaved twice as efficiently compared 
to MA/CA sequence when short peptide models are tested for substrate cleavage (Tritch 
et al., 1991). However, most of the kinetic data on substrate cleavage by HIV protease is 
acquired under different experimental set ups and warrants caution while drawing 
conclusions as the ionic strength and the pH of the reactions greatly affect critical factors 
like protease dimerization constant, substrate affinity and the catalytic rate of reactions 
(Beck et al., 2000; Hyland, Tomaszek, and Meek, 1991; Ido et al., 1991; Polgar, Szeltner, 
and Boros, 1994).  
The dimeric protease with its flaps closed, forms a binding ‘tunnel’ that can discriminate 
substrates based on the identity of amino acids in the P4-P3’ positions around the scissile 
bond (Tozser et al., 1991; Weber et al., 1989). In an effort to define the specificity of HIV 
protease, several rules identifying the specificity determinants have been proposed 
(Henderson et al., 1988; Pettit et al., 1991). These studies explored the preferential 
identity of amino acids at each position in the P4-P3’ substrate sites. Computationally 
intensive (Poorman et al., 1991) and volume based methods (Chou et al., 1996) for 
determination of amino acid preferences at certain positions in a data set have also been 
employed to identify cleavage sites. While these methods can predict and identify 
substrates with high frequency, they are of limited advantage in deciphering the context 
dependence and rate of cleavage of each substrate. 
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Various protease-substrate kinetic experiments conducted with modified substrate 
cleavage sites for protease have (Beck, Morris, and Elder, 2002; Pettit et al., 2002) 
probed the effects of amino acid substitutions at all substrate sites (P4-P4’). These studies 
suggested the importance of P1 residue in directing substrate recognition and cleavage 
(Pettit et al., 2002; Prabu-Jeyabalan et al., 2006). Structural studies on protease-substrate 
complexes (Prabu-Jeyabalan, Nalivaika, and Schiffer, 2000; Prabu-Jeyabalan et al., 2006) 
proposed the conserved shape, “substrate envelope” to be crucial for substrate specificity. 
Substrate envelope demonstrated that compared to the P1’-P3’ residues, larger volume is 
conserved for the P3-P1 substrate subsites across the structures and (P3-P1) region of the 
substrate is, therefore, crucial for substrate recognition.  
Taking precedence from these studies implicating the importance of (P3-P1) region in 
substrate recognition, we investigated structurally, whether there is a binding preference 
for P site substrate sequence over P’ site sequence for HIV protease. We crystallized 
active wild type (Q7K) HIV-1 protease in complex with five of its natural substrate site 
decameric peptide analogues (Table IV.1). Protease cleaved all the substrate peptides and 
crystallized with P side product (P3-P1) bound to its active site demonstrating greater 
affinity for the P site substrate sequence compared to the P’ site. These structures 
establish the importance of (P3-P1) region in substrate recognition supporting the 
hypothesis that N terminal substrate sequence plays a significant role in determining 
protease-substrate binding specificity.  
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Table IV.1. The thirteen recognition sequences cleaved by HIV-1 protease. The 
substrate cleavage sites used for crystallization in this study are highlighted in bold. Also 
shown are the N terminal substrate sequences as observed in the Q7K-product bound 
structures for MA-CA, RH-IN, p1-p6, RT-RH and CA-p2 sequences. The N terminal (P 
side) product was observed on both sides of the substrate binding tunnel in CA-p2 
complex and is highlighted in red. * denotes the scissile bond. # represents host protein 
targeted for cleavage by HIV-protease (Perales, Carrasco, and Ventoso, 2003; Ventoso et 
al., 2001).  
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Table IV.1  
WT Substrate sequences Cleavage sites Sequences observed in product 
bound structures 
P4
 
P3
 
P2
 
P1
 
P1
’ 
P2
’ 
P3
’ 
P4
’   
SQNY*PIVQ MA-CA SQNY* 
RKIL*FLDG RH-IN RKIL* 
ARVL*AEAM CA-p2 RVL*LVAA 
PGNF*LQSR p1-p6 GNF*LQ 
AETF*YVDG RT-RH AETF*YVD 
ATIM *MQRG p2-NC - 
RQAN*FLGK NC-p1 - 
RQAN*FLRE NC-TFP - 
DLAF*LQGK TFP-p6 - 
SFNF*PQIT p6-PR - 
TLNF*PISP PR-RT - 
DCAW*LEAQ NEF - 
TVL*MTED 
RFSA*LQQA 
eIF4GI# 
eIF4GI# 
- 
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RESULTS 
Overall structure of the complexes   
The five decameric substrate peptides for MA-CA, CA-p2, p1-p6, RH-IN and RT-RH 
cleavage sites were crystallized in complex with active variants of WT HIV-1 protease. 
Crystals were successfully grown and data obtained for all complexes.  Structures were 
solved for all complexes, to a resolution between 1.7 – 2.2 Å (Table IV.2). All the 
complexes are solved in the P212121 with one molecule in the asymmetric unit. All 
substrates crystallized with the active protease are cleaved and the crystal structures are 
product bound complexes of HIV protease with N terminal (P side) product bound in the 
active site (Table IV.1).   
While all other poducts are uniquely oriented in the crystal structures, RT-RH products 
are present in more than one orientation with respect to the protease dimer. Both the 
products resulting from the RT-RH cleavage are therefore, modeled and analysed in both 
possible orientations in the crystal structure. For the uniquely oriented P side products, 
there is some disordered and discontinuous electron density in the S’ binding cavity. 
However, in the CA-p2 product complex, the P side product is distinctly present in both 
sides of the active site (S and S’).  
All product bound structures are similar to the previously solved WT-substrate structures, 
with RMSD ranging from 0.13 to 0.2 (Fig IV.1a-e). However, backbone shifts are 
observed in the flap-hinge region for all complexes analyzed. Backbone shifts are also 
observed at residues 80-82 in CA-p2 complexes and residues 30-34 in RH-IN complexes. 
150
  
While residues 80-82 form part of the protease active site, residues 30-34 are part of the 
protease core region that is known to be flexible. The differences in the flap-hinge region 
are likely due to the effect of crystal packing.  The changes in the active site and core 
region are likely due to the altered symmetry of the protease dimer upon binding much 
shorter products compared to the substrates in the PRWT—substrates structures. These 
structural alterations will be described in the following sections.  
For all structures used in the analyses, including the previously solved PRWT—substrates, 
three product residues from P1 to P3 sites were unambiguously located within the 
electron density map.  All the peptide products bound to the protease in the same 
extended conformation similar to the PRWT—substrate complexes (Prabu-Jeyabalan, 
Nalivaika, and Schiffer, 2000; Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002). The P 
side products superposed very well with their respective P side sequences in the PRWT—
substrates complexes (RMSDs 0.12-0.16). In some of the complexes, certain disordered 
residues from the P’side product are also observed. Curiously, in Q7K-CAp2 complex, 
two copies of the P side product is present such that the entire binding site has two 
repeats of P side CA-p2 product present successively from amino to carboxyl direction, 
confirming higher affinity of protease for the (P3-P1) substrate sequence compared to the 
P’ side sequence (Table IV.1). 
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van der Waals interactions and Hydrogen bond network 
Similar changes in the overall van der Waals interactions are observed in all the product 
bound structures compared to the PRWT—substrate structure. With the exception of 
increased interactions between D25A and the P1 terminal oxygens, observed for all 
product bound structures, analysis of the van der Waals interaction energies of the active 
site residues show similar interactions between active site residues of monomer A and the 
P side product in all five product complexes. 
To investigate if there are any changes in the mode of binding, hydrogen bonding 
interactions between the P side product and the surrounding protease residues were 
analyzed. The presence of aspartic acids (D25) instead of asparagine (N25) in the Q7K-
product structures is observed to make additional hydrogen bonds with the terminal 
oxygens (OXT) at the P1 scissile bond site across all the structures. The backbone 
hydrogen bonding pattern is maintained between protease and the (P3-P1) product 
residues. Any differences observed in the hydrogen bonding and van der Waals 
interaction analyses between the product vs. substrate structures could be explained by 
slight shifts and/or subtle differences in the side chain orientations of the amino acids 
involved.  
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Table IV.2.  Crystallographic statistics for active (Q7K) protease complexes with the 
five substrate peptides.     
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Table IV.2 
Variable Q7K-RHIN Q7K-MACA Q7K-CAP2 Q7K-P1P6 Q7K-RTRH 
Data collection      
Resolution (Å) 1.7 2.2 1.9 1.85 2.0 
Temperature (°C) 100 100 100 100 100 
 Space group P212121 P212121 P212121 P212121 P212121 
a (Å) 50.78 50.7 50.8 50.9 50.9 
b (Å) 58.1 58.2 58.3 58.3 58.3 
c (Å) 61.8 61.6 61.6 61.7 61.7 
Z 4 4 4 4 4 
R merge (%) 5.8 8.4 8.6 6.8 9.3 
Completeness (%) 99.7 100 99.9 99.7 94.8 
Total Reflections 176267 74236 114838 103996 81841 
Unique Reflections 22603 9711 14927 16269 12171 
I/σi 11.8 10.6 9.3 11.9 9.8 
RMSD in:      
Bond length (Å) 0.009 0.009 0.009 0.009 0.009 
Bond angles 1.344 1.479 1.403 1.392 1.416 
R value (%) 16.99 16.52 16.74 16.71 18.41 
R free (%) 19.33 20.69 22.25 19.56 20.46 
  Redundancy 7.8 7.6 7.7 6.4 6.7 
 
Ambiguous electron 
density 
  Residual 
unresolved 
density in the 
active site 
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Figure IV.1. Superposition of the Q7K-product complexes over the PRWT-substrate complexes from protein data bank. 
(a) Superposition of RT-RH complexes. Both orientations of the RT-RH products are shown superposed over the pdb id 1KJG.  
(b)  Superposition of protease complexes with CA-p2 products and CA-p2 substrate (1F7A) (c) Superposition of protease 
complexes with MA-CA product and MA-CA substrate (1KJ4). (d) Superposition of protease complexes with p1-p6 product 
and p1-p6 substrate (1KJF). (e) Superposition of protease complexes with RH-IN product over RH-IN substrate (1KJH)
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Figure IV.1 
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Figure IV.1 (cont.) 
 
  
DISCUSSION 
In order to investigate the importance of N terminal (P3-P1) substrate region in 
recognition specificity by HIV protease, the catalytically active HIV protease was 
crystallized with five known substrate cleavage site sequences (Table IV.1). The active 
protease was expected to cleave the substrate peptides and predicted to crystallize with N 
terminal substrate (P side product), only if the relative affinity of binding of P side 
sequence is greater than the P’ side sequence and the binding is driven by this affinity of 
interaction. The co-crystals obtained were all product-bound complexes of protease with 
P side product sequence crystallized within the protease active site in all of the structures 
determined. Some remnants of C terminal product were also observed in some of the 
structures but are far less ordered. While the N terminal product complexes with MA-CA, 
RH-IN, p1-p6 showed uniquely oriented N terminal product only, CA-p2 complex 
showed N terminal product bound on both sides of the cleavage site such that for both 
products, P1 residue is aligned next to the catalytic aspartic acids. This structural work 
demonstrates the preferential affinity of N terminal substrate sequences over C terminal 
in protease-substrate binding interactions. 
Polyprotein processing is highly sequential and regulated; however, the influence of 
kinetic intermediates on this regulation is poorly understood. The structural data on N 
terminal product complexes of protease raises the question: could there be a potential N 
terminal product inhibition in the polyprotein turnover by HIV protease? Addressing this 
question requires detailed kinetic studies; the results of which could be potentially useful 
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in understanding the temporal regulation of viral maturation process. The regulation of 
protease function in vivo, however, will also depend on the exposure time of the potential 
cleavage site that in turn depends on the stability of the global conformation of the 
polyprotein. Earlier structural studies have confirmed that the substrates bind to the 
protease active site in an extended β - sheet conformation; however, dependence of 
protease specificity on the conformational context of the Gag-Pro-Pol polyprotein 
remains largely unexplored and the structural data for the Gag-Pro-Pol polyprotein that 
could facilitate this confirmation is still lacking. Due to these gaps in our knowledge of 
HIV viral proteins, understanding substrate specificity in HIV protease remains 
incredibly challenging.  
Nevertheless, while various substrate classifications and hypotheses regarding the factors 
determining substrate specificity for HIV protease, abound the literatures, the underlying 
mechanism still remains unknown. In this study, we provide structural confirmation that 
for HIV protease, there exists a preferential binding affinity for the P side (N terminal) 
sequence of substrates over P’ sequence (C terminal). Since N terminal of substrate 
sequences is previously reported to regulate substrate processing in other pathogenic viral 
enzymes, including Hepatitis C NS3 protease (Steinkuhler et al., 1998; Yao et al., 1999), 
our further interest is to investigate in detail the role of kinetic intermediates in substrate 
processing by HIV protease.  
 
 
159
  
MATERIALS AND METHODS 
Nomenclature.  HIV-1 protease variants (q7k/active or D25N/inactive) and the product 
complexes will be distinguished throughout this chapter.  For example, active protease in 
complex with MA-CA product is denoted by q7k-MACA and the previously solved 
inactive protease-substrate complexes are denoted by the pdbID-substrate name (1KHJ-
RH-IN). Monomer A and monomer B residues are distinguished in subscripts. 
Substrate peptides.  Decameric peptides corresponding to the five processing sites 
within the Gag polyprotein (MA-CA, CA-p2, p1-p6, RH-IN and RT-RH) were purchased 
from Quality Controlled Biochemicals, Inc., Hopkinton, MA. The following peptide 
variants were used in the x-ray crystallographic structural studies described in the 
subsequent sections:  
(1) Q7K/MACA – VSQNY*PIVQN (2) Q7K/p1p6 – RPGNF*LQSRP (3) Q7K/RHIN 
IRKIL*FLDGI (4) Q7K/CAp2– KARVL*AEAMS (5) Q7K/RTRH- GAETF*YVDGA  
Protease gene construction.  The clade B wild-type (WT) protease gene was constructed 
synthetically using codons optimized for protein expression in Escherichia coli as 
previously described with the Q7K mutation introduced to prevent autoproteolysis (Rose, 
Salto, and Craik, 1993a). Mutations were introduced using the Quik-Change™ site-
directed mutagenesis kit (Stratagene ®, La Jolla, CA) and confirmed by sequencing.  
Protein expression and purification.  Expression and purification of active Q7K 
protease variants was performed as previously described (Prabu-Jeyabalan et al., 2004b).  
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Briefly, the protease gene was sub-cloned into the heat-inducible pXC35 expression 
vector (American Type Culture Collection (ATCC), Manassas, VA) and transformed into 
E. coli TAP-106 cells.  Transformed cells were grown at 30°C till A600= 0.7 and induced 
by raising the temperature to 42°C.   Cells were allowed to grow for 4 hours and lysed to 
release the protease-containing inclusion bodies.  The protease was extracted with 50% 
acetic acid and purified by gel filtration on a 2.1L Sephadex G-75 superfine (Sigma 
Chemicals) column equilibrated with 50% acetic acid.  The purified protease was 
refolded by rapid 10-fold dilution into a buffering solution (refolding buffer) containing 
0.05 M sodium acetate (pH 5.5), 10% glycerol, 5% ethylene glycol, and 5mM 
dithiothreitol.  The refolded protein was concentrated and dialyzed to remove any 
residual acetic acid.  The protease was further purified with a Pharmacia Superdex 75 fast 
performance liquid chromatography (FPLC) column equilibrated with refolding buffer. 
Crystallization and data collection.  Crystals used in this study were obtained under 
multiple conditions.  Q7K protease solutions between 1.0 and 1.5 mg mL-1 with a ten-
fold molar excess of the substrate peptides, individually, with no incubation, were used 
for setting up crystal drops.  Crystals were grown by the hanging drop vapor diffusion 
method over a reservoir solution consisting of one of the following two buffer solutions – 
1) 126-mM sodium phosphate buffer (pH 6.2), 63-mM sodium citrate, and 20% to 32% 
ammonium sulfate  2) 0.1M citrate (pH 5.5), 0.5-3.0M ammonium sulphate.  X-ray 
diffraction data for Q7K-product complexes was collected on the beamline X29A at the 
National Synchrotron Light Source (Brookhaven National Laboratories, Upton, NY) at a 
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wavelength tuned to 1.08 Å with a Quantum 315 CCD X-ray detector (Area Detector 
Systems Corporation, Poway, CA). All data were collected under cryo-cooled conditions. 
Structure solution and crystallographic refinement.  The data were indexed and scaled 
using HKL-2000 software (HKL Research, Charlottesville, VA). Structures were solved 
and refined using the CCP4 program suite (Collaborative-Computational-Project, 1994).  
The Matthews co-efficient was calculated for all structures to determine the number of 
molecules in the asymmetric unit.  For complexes, structure solution was carried out 
using the molecular replacement package Phaser (McCoy et al., 2007). ARP/wARP was 
used to build solvent molecules into the electron density (Langer et al., 2008).  
Refinement was carried out using a combination of TLS (Winn, Isupov, and Murshudov, 
2001) and restrained refinement using Refmac5 (Murshudov, Vagin, and Dodson, 1997). 
Each cycle of refinement was followed by model building and real space refinement 
performed using COOT, a molecular-graphics software (Emsley and Cowtan, 2004).  For 
all complexes, the peptide products were built into the Fo-Fc electron density after two 
rounds of refinement cycles.  The working R (RWork ) and its cross validation (RFree ) were 
monitored throughout refinement.  The quality of the structures was assessed using 
MolProbity (Davis et al., 2007). 
Structure Analyses. Comparisons of the crystal structures were made by superposing Cα 
atoms of the active site and C terminal regions (residues 24 to 26 and 86 to 99) from both 
monomers onto a previously solved structure of WT protease substrate complexes (PDB 
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1KJF; 1KJG; 1F7A; 1KJG; and 1KJ4) (Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002).  
Structures were visualized using PyMol molecular-graphics software (DeLano, 2002a). 
Hydrogen bonds and van der Waals contacts. Hydrogen bond interactions were 
determined using the Hydrogen Bond Calculation version 1.1 program 
(http://cib.cf.ocha.ac.jp/bitool/HBOND/).  van der Waals interaction energies between 
protease and the peptide products were computed using a simplified Lennard-Jones 
potential, V(r) using the relation 4ε[(σ/r)12 – (σ/r)6], where r is the protease-substrate 
interatomic distance and ε and σ are the depth of the potential well and collision 
diameter, respectively for each protease substrate atom pair. V(r) is computed for all 
possible protease-product atom pairs within 5.0 Å and potentials for nonbonded pairs 
separated less than a distance at the minimum of the potential were equated to - ε.  Using 
this simplified potential for each non-bonded protease-product atom pair, total van der 
Waals contact energy, ΣV(r) was then computed for each protease and each product 
residue in all of the analyzed complexes. 
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CHAPTER V 
DISCUSSION 
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In the year 2011, HIV-AIDS continues to pose a threat to global health. There is no cure 
for AIDS nor a vaccine to prevent HIV infection. Inhibiting the progression of HIV 
infection and improving the lives of people infected with HIV has been the main focus of 
scientific research in HIV studies. Designing drugs to inhibit the key enzymes involved in 
viral replication has been remarkably successful in controlling the spread of AIDS. HIV-
1 protease is an important drug target as protease activity is required for the maturation 
and infectivity of new virions. Despite the availability of highly effective inhibitors of 
protease activity, under selective pressure of drugs, protease mutates to evade drug 
binding while preserving substrate recognition. Therefore, the main focus of the 
continuing HIV research is to gain complete understanding of the biology of this virus as 
it affects human host cells, and develop robust drugs less susceptible to resistance.    
CONCLUSIONS 
The primary focus of my dissertation research was to address the fundamental 
mechanistic question: how protein flexibility modulates 1) function, 2) substrate 
recognition and 3) drug resistance pathways in HIV-1 protease. Ligand binding and 
release are dynamic processes and, therefore, regulated by intrinsic protein flexibility. 
Mutations that could change the dynamic properties of protease could also modulate the 
ability of protease to bind to its substrates and inhibitors. And the mutations that 
preferentially affect inhibitor binding over substrate binding would then lead to drug 
resistance. A combination of biochemical (substrate cleavage assays), biophysical 
(molecular dynamic simulations (MD), Isothermal titration calorimetry (ITC)), and 
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structural studies were performed to demonstrate the interdependence of substrate 
recognition and drug resistance on protein dynamics. 
Protein flexibility in protease function 
Conformational flexibility in proteins is often linked to protein function. However, there 
is limited experimental evidence to establish the regulation of protein function by internal 
protein dynamics. In chapter II, I demonstrate that the protein function is directly 
modulated in response to the internal hydrophobic core dynamics in HIV-1 protease. This 
modulation of protease activity through alterations in the internal dynamics is the first to 
be experimentally demonstrated and is likely a general mechanism by which protein 
dynamics regulates protein function. This is especially significant as drug resistant 
mutations in protease occur not only within the active site but also outside the active site 
at distal locations (Clemente et al., 2004; Foulkes-Murzycki, Scott, and Schiffer, 2007; 
Muzammil, Ross, and Freire, 2003; Rhee et al., 2010). While active site mutations 
directly interfere with inhibitor binding, the role of mutations remote from the active site 
is harder to explain. I hypothesize that these mutations, perhaps, generate novel 
conformational heterogeneity in the protease molecules, such that there is a preferential 
selection for the conformers that bind substrates over inhibitors.  
Using site directed cysteine cross-linking I reversibly probed the functional implications 
of restricting hydrophobic core dynamics on HIV-1 protease enzyme function. 
Complementing these studies crystal structures were determined and molecular dynamics 
simulations performed on protease in the presence and absence of cross-linking to 
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estimate the conformational flexibility of protease hydrophobic core. These results 
demonstrate that restricting hydrophobic core dynamics via disulfide bonding leads to 
loss of protease activity and that the activity is substantially rescued upon reducing the 
disulfide bonds.  
This paradigm of functional modulation likely extends to all proteins that undergo 
dynamics, as well as to the understanding of the many medical targets that are susceptible 
to drug resistance.  
Designing specificity in protease 
Defining factors that govern substrate recognition in HIV protease has been an active 
area of investigation. While previous studies have investigated the ability of a 
polypeptide sequence to serve as a viable protease substrate (Griffiths et al., 1992; Pettit 
et al., 1991; Ridky et al., 1996; Tozser et al., 1991; Tozser et al., 1992; Tozser et al., 
1997b), the study presented in chapter III explored what residues provide the protease 
with the ability to recognize these polypeptides as substrates. The knowledge of protease 
active site residues crucial for substrate recognition could provide insights into the 
protease-substrate interactions and this knowledge could further be exploited to design 
better drugs less susceptible to drug resistance. Using computational positive design, 
specificity towards one of its natural substrates was tailored within the protease. Design 
predictions were experimentally validated by ITC and X-ray crystallography studies. The 
results demonstrated that A28, D30 and G48 positions contribute significantly to the 
process of substrate recognition and binding in HIV protease and specificity can be 
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engineered in a given protein by optimizing the hydrogen bonding interactions between 
the protein and its ligand. Because the inherent protein flexibility cannot be fully defined 
by the current computational design algorithms, limited correlation was observed 
between structural data and design predictions. Therefore, these results not only give 
insights into the determinants of substrate specificity in protease but also highlight the 
importance of protein flexibility in substrate recognition.  
Substrate recognition in protease 
The N terminal (P3-P1) region of the substrates has been previously hypothesized to be 
important in substrate binding by HIV-1 protease (Pettit et al., 2002; Prabu-Jeyabalan, 
Nalivaika, and Schiffer, 2000; Prabu-Jeyabalan et al., 2006). In chapter IV, I examined 
the structural basis of substrate binding in protease by crystallizing active protease in 
presence of five decameric substrate sequences corresponding to MA-CA, p2-NC, CA-
p2, RT-RH and RH-IN cleavage sites, respectively. The structural analysis revealed that 
for all five complexes protease crystallized with N terminal substrate sequence bound in 
the protease active site. The N terminal substrate positions P3-P1, were identified and 
modeled in all five product complexes of protease. The C terminal substrate was either 
missing or displayed disordered electron density. Thus, the structural work presented in 
chapter IV, demonstrates that protease exhibits preferential affinity towards N terminal 
substrate sequence compared to the C terminal sequence.  
 Since HIV protease substrates are non-homologous and asymmetric (de Oliveira et al., 
2003) in their cleavage sites, the observed preferential affinity for the N terminal 
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substrate sequences (P3-P1) for all five substrates analyzed cannot be explained on the 
basis of cleavage site sequence alone. Further studies are required to understand and 
differentiate between the termini specific vs. residue specific contribution towards 
determination of substrate specificity in HIV protease.  
These product complexes also advance an idea of whether there is a physiological 
relevance to the N terminal product bound in the active site. The Gag-Pro-Pol polyprotein 
processing is a sequential event that is highly regulated and could be influenced by 
kinetic intermediates at every step. Since product release is the rate determining step in 
enzymatic reactions, our further interest is to investigate in detail if the higher affinity of 
the N terminal product as seen in crystal structures, catalytically affects the rates of 
sequential steps during polyprotein processing. These experiments could provide crucial 
insights into the spatiotemporal regulation of viral maturation process. 
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FUTURE DIRECTIONS 
Hydrophobic core flexibility and modulation of protease function 
I have shown, in chapter II, that hydrophobic core flexibility modulates protease function 
and presented a hypothesis that non-active site drug resistance mutations potentially 
contribute to drug resistance by modulating this dynamics. The kinetic studies to 
quantitate protease function were performed using CA-p2 substrate cleavage site. FRET 
(fluorescence resonance energy transfer) based kinetic assay used to obtain kinetic rate 
constants for substrate cleavage was limited in its ability to measure discrete KM and kcat 
values because of limited solubility of the labeled substrate in the kinetic buffer. 
Therefore, although the protease with restricted flexibility demonstrated extremely poor 
Michaelis-Menten kinetics compared to its non-restricted counterpart (Fig. V.1), only 
specific activity (kcat/KM) could be measured. These results implore the question of 
whether the difference in specific activity is due to the difference in binding process (KM) 
vs. the actual catalysis (kcat). Additional experiments to tease out the catalytic parameters 
into kcat and KM will provide insights into the exact mechanism by which catalysis is 
being slowed by disulfide cross-linking in the hydrophobic core.  
Additionally, it would be interesting to know what the disulfide does to the affinity for 
DRV or another inhibitor. These inhibitor affinity studies, if conducted in the presence of 
secondary drug resistance mutations in the background of flexibility restricting disulfides 
would provide mechanistic insights into the contribution of non-active site mutations in 
drug resistance. I believe that this system we have setup provides a downstream route to 
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test out panels of mutations and when combined with MD on these mutants will provide 
additional information on drug-resistance and hydrophobic sliding. 
Also, since protease recognizes and cleaves 13 substrates at different rates, investigating 
whether there is a differential loss of activity for some specific substrates over the others, 
and if the order of polypeptide cleavage is somehow affected upon restricting the core 
mobility within the protease will be potentially interesting questions to address. 
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Figure V.1: Preliminary Michaelis-Menten kinetic curves for substrate cleavage by 
WTcysless, flexibility- restricted and un-restricted HIV protease. Compared to the 
unrestricted protease, flexibility-restricted protease is dramatically worse in its kinetic 
profile for the cleavage of CA-p2 substrate site. The activity of the WT protease in a 
cysteine free background is comparable to that of the unrestricted protease.  
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Figure V.1  
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Substrate recognition specificity in protease 
The product bound complexes of protease demonstrate the preferential binding affinity of 
protease towards N terminal substrate sequence and also present the possibility of N 
terminal product inhibition in protease. As product release is the rate-limiting step in 
enzymatic reactions, uncovering potential product inhibition could be the key to 
understanding the regulation of polyprotein during viral maturation. Thus, detailed 
kinetic experiments can be conducted to test the potential product inhibition in protease- 
substrate cleavage reaction as previously described for hepatitis C NS3 protease system 
(Yao et al., 1999). If product inhibition could be established in protease, sequential 
product inhibition during Gag-Pro-Pol processing can further be investigated by 
monitoring the disappearance of labeled substrate in the presence and absence of 
unlabeled forms of substrates from preceding sequential cleavage.  
Significance and implications for treatment and drug design strategies 
Drug resistance develops against all currently available drugs to treat HIV-AIDS. The 
mutations that cause resistance to drugs are strictly non-random and widely distributed 
within the enzymes used as drug target. In this thesis research, we focused on HIV 
protease and resistance to PIs. While we understand the mechanism behind some of the 
resistant mutations that directly interfere with PI binding, the influences of indirect 
pathways leading to resistance are harder to explain. All PIs currently used are active site 
competitive inhibitors; therefore, drug resistance in protease is a change in molecular 
recognition where substrate recognition is preserved while preventing inhibitor binding. 
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All resistant proteases maintain their ability to bind and cleave their natural substrates. 
Hence, understanding the process of substrate recognition and specificity is critical in 
developing drugs in a manner that drugs not just mimic the binding, but also bring about 
similar conformational changes involved in formation of transition state complex and 
product release, as initiated by substrate binding. Nonetheless, these processes are 
dynamic events that are not easy to understand.  
The work presented in this thesis research enhances our understanding of these dynamic 
processes that address various aspects of protease function. The knowledge that protease 
activity is modulated by the conformational changes in protease hydrophobic core could 
be exploited to design inhibitors to freeze this dynamics. Since, protease cleaves multiple 
substrates in an ordered fashion and at distinct rates, understanding the regulation of this 
order and rates of cleavage is vital to inhibit the formation of mature, infectious virus. 
The work done on specificity designed protease exploited synergistic utilization of 
computational methods to further our understanding of substrate recognition in protease. 
This is a step forward in our ability to precisely engineer enzyme functions as 
biocatalysts and has immense potential in the field of medicine and industry. The 
capability to accurately predict and design macromolecular structures and interactions 
would provide more complete understanding of forces underlying the complex processes 
like protein folding.  
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